Experts Weigh in on Evaluating, Treating Comorbid Migraine and Temporomandibular Dysfunction – Neurology Advisor

Headache and orofacial pain are complaints commonly reported in the same patient, particularly in children and adolescents. In patients with migraine, comorbid temporomandibular dysfunction (TMD) can lead to an increase in migraine frequency and use of migraine medications.

For further insight regarding the diagnosis and management of this patient population, we spoke with Paul G. Mathew, MD, a headache, sports neurology and concussion specialist with Brigham and Womens Hospital at Harvard Vanguard Medical Associates and Assistant Professor of Neurology at Harvard Medical School in Boston, MA, as well as Steven D. Bender, DDS, the Director of Facial Pain and Sleep Medicine with the Department of Oral and Maxillofacial Surgery at Texas A&M College of Dentistry in Dallas, TX. Both Dr Mathew and Dr Bender uniquely encounter patients with TMD and migraine in their respective practices, and shared their personal experience and advice for managing this often overlooked comorbidity.

How did you first become interested in TMDpathology?

Dr Mathew: First of all, I ammarried to a dentist, and so I have learned quite a bit about dentistry throughmy wife, which includes some of the nuances of how dental issues can impactmultiple aspects of health and wellbeing. I have also served as faculty for theTufts Headache and Face Pain Symposium, which brings together dentists andphysicians for a highly interactive 2-day program that explores the overlapsbetween craniofacial pain and orofacial pain.

Overmany years of practice, I have treated a growing number of patients who, duringa headache history, mention that they also have jaw pain. Unfortunately, afterseeking help from general dentists, pain clinicians, and even oromaxillaryfacial surgeons who may offer invasive surgical procedures, only a smallpercentage of patients end up being seen by an orofacial pain specialist, adentist with specialized training in the treatment of disorders including TMD.

Dr Bender: I became interestedin TMDs when I was in dental school and then began to study it more earnestlysoon after graduation due to my own jaw pain. Also, my wife developed seriousTMD pain shortly after I graduated from dental school and I couldnt findanyone who had the knowledge to help her.

What arethe primary mechanisms that can cause both TMD and migraine pain?

Dr Bender: A number of papersdescribe the incidence of these 2 disorders occurring together, although themechanisms that may be involved are yet to be fully described. There is thoughtthat convergence of nociceptive information into the trigeminal nucleuscaudalis plays a major role in sensitizing the central nervous system (CNS).So, if one has migraine, which is thought to be a disorder where the CNS ismore easily sensitized, and you add nociceptive input from other parts of thetrigeminal system as seen with TMD, the cascade of events leading to a migrainemay be more easily initiated and the patient will experience more frequent andintense migraine events

How do you identify TMD in a patient withmigraine?

Dr Mathew: The big issue here is making thediagnosis. Most patients either assume there is nothing that can be done,or they are told by doctors or dentists that they do not treat jaw issues. Assuch, many patients abandon hope of getting treatment, and may never even seekadditional care. In my experience, most patients do not mention this complaintwhen they present for a headache evaluation, so part of my examination includesevaluating jaw range of motion and palpating the joint, as well as examiningthe teeth and oral cavity looking for oral pathology. If there are anysignificant findings, I will ask questions about grinding, clenching, andwaking up in the morning with jaw tightness and pain.

Dr Bender: As migraine can sometimes present as a toothache or other facial pains, it is important for the provider to be familiar with the diagnostic ICHD 3 criteria of migraine, (ie, a headache that has at least 2 of the following qualities: primarily unilateral, pulsatile, of moderate to severe intensity and/or is aggravated by activity as well during the attack having one of the following: nausea and or vomiting and/or a sensitivity to light and sound, and a duration of the orofacial pain 4-72 hours which then remits) could be indicative of a migraine presentation.1

The human body does not have systems in isolation, so if you have TMD, it can serve as a trigger for migraine.

How important it is to recognize and diagnoseTMD?

Dr Mathew: It is very important to make the diagnosis of TMD. If a patient has pain with opening and closing the mouth, it can become very difficult to eat and to talk. In addition, the loud popping and clicking that is often associated with TMD can be socially embarrassing. The human body does not have systems in isolation, so if you have TMD, it can serve as a trigger for migraine. Studies have demonstrated that if you have both migraine and TMD, adequate treatment of TMD can lead to the improvement of the frequency and intensity of migraine. In other words, untreated TMD can make it more difficult to adequately treat migraine.

What diagnostic criteria do you use and why? Do you use any tests to confirm?

Dr Bender: While its certainlynot perfect, I use the ICHD 3 diagnostic criteria for headache disorders. A newclassification for orofacial pains was recently published and may prove usefulfor standardizing the diagnosis of orofacial pains.2 Also, theDiagnostic Criteria for Temporomandibular Disorders (DC/TMD) has been used forsome time both in the research arena and clinical practice.3 TheDC/TMD also outlines validated examination techniques of the relevant structuresinvolved in temporomandibular disorders.

Ultimately the confirmation will come from the preclinical interview and examination.

Ultimatelythe confirmation will come from the preclinical interview and examination. Additional testing will be directed by the history andexamination. New onset headaches and neuropathic pains should usually be imagedwith MRI and/or CT, although in most cases, TMDs dont necessarily requireadvanced imaging to establish a diagnosis. Laboratory studies are typically notindicated unless the pain presentation is suspected to be a manifestation of asystemic etiology.

Why is aneurological assessment important when a patient has symptoms indicative of TMD?

Dr Bender: A neurologicscreening, especially a cranial nerve screening, is an important aspect of anevaluation for most non-odontogenic facial pains like TMDs, neuropathies,neuralgias and headache disorders, particularly if a patient has developed arelatively new onset headache. Conversely, in a neurologic practice, theclinician should become familiar with examination techniques to assess thestomatognathic structures (muscles of mastication, cervical muscles andtemporomandibular joints).

Whatinterventions are used to manage these 2 conditions?

Dr Mathew: My first recommendation is that patients see a dentist, preferably an orofacial pain specialist. If they are clenching or grinding, a night guard can be useful. A night guard is a custom-made appliance that can accomplish a few things: 1) Protection of tooth enamel from wear associated with nocturnal clenching/grinding, 2) Prevention of migration of the teeth within the gums and the development of gaps, and 3) Reduction at times of the forces generated from clenching and grinding, which may help reduce tension/pain within the muscles of mastication and the temporomandibular joint.

Second,I advise patients to avoid activities that can exacerbate symptoms, such aschewing very tough things like steak or sticky candy, which can serve astriggers.

Third,a physical therapy referral can be very useful, especially if thetherapist is well versed in the management of migraine and TMD. By treating TMD, neighboring muscle groupsmay benefit. If TMD/neck pain and tightness improve, there is a tendency formigraine frequency and intensity to also improve, so a physical therapist canbe very helpful in addressing coexisting posture and ergonomic issues. Mostorofacial pain specialists can recommend a local/regional physical therapistwho specializes in the management of TMD.

Lastly,I often recommend the use of pharmacological treatments including medicationslike muscle relaxants and Botox [onabotulinumtoxinA] injections to manage painfrom both migraine and TMD.

Dr Bender: Many patients I see have previously consulted with multiple providers for their headaches and TMDs who did not consider the comorbidity of these disorders. I explain to the patient that in most cases, if we can decrease nociceptive information entering the trigeminal system from the stomatognathic structures we will be better able to successfully treat both disorders. With TMDs, we try to start with very conservative measures such as self-care therapies (resting the jaw, ice/heat, limiting certain foods, jaw mobilization techniques and in some cases over the counter analgesics). We may also refer to a physical therapist trained in caring for TMD patients.

Many patients I see have previously consulted with multiple providers for their headaches and TMDs who did not consider the comorbidity of these disorders.

In selected cases of refractorymasticatory muscle pain, the judicial use of low doses of botulinum toxin maybe helpful. The potential benefits of this therapy must be weighed against therisk of osteopenic changes to the involved bony structures.4 Selectivenerve blocks and muscle trigger point injections may also be of benefit forsome patients.

Pharmacotherapy (muscle relaxers,anti-inflammatories/analgesics) can be beneficial for some patients but in mostcases, it is not needed for most TMDs. A custom fabricated intra oral deviceworn on the teeth (commonly termed an oral splint, night guard or oralorthotic) will benefit many TMD presentations if well designed and constructedspecifically for the individual patients presentation. More invasive andirreversible therapies such as orthodontics, jaw repositioning procedures, jawsurgeries or bite adjustments should be avoided as these therapies lackevidence and can potentially create even more significant pain. The well-managedTMD patient with a concomitant headache disorder will often find that theyrequire less prophylactic and abortive medications.

Arethere other types of therapies (drugs, surgical techniques, patient-appliedtherapies) that may also help?

Dr Bender: Along with the above therapies, we give the patient self-care instructions to try to decrease sympathetic tone. We will talk to them about behavior modification techniques to stop the habit of awake teeth clenching or bracing. Even light nonfunctional tooth contact has been shown to elicit muscle activity which can add to nociceptive signaling. We also instruct our patients in physical self-regulation based on the work of Carlson et al5 in which patients follow a somewhat structured program designed to decrease sympathetic tone. This will include proper hydration and nutrition, diaphragmatic breathing, posture awareness, adequate sleep, and focused relaxation.

Manypain patients have previously undiagnosed sleep disorders. In our practice, a part of our initial evaluation willinclude screening for these disorders with questionnaires and the use of homepulse oximetry to screen for sleep related breathing disorders. In many cases,treating the underlying sleep disorder has significantly reduced our patientsheadache and TMD complaints.

A clinical psychologist trained inpain management can also help patients better manage thoughts and behaviorsoften associated with chronic pain.

How well dopharmacological treatments like Botox work?

Dr Mathew: Oral medications (like muscle relaxants) can be effective, but many patients have difficulty tolerating them. In other cases, patients would prefer not to take a daily oral medications. As such, patients are often quite happy with receiving Botox injections every 3 months, given the convenience and a favorable side effect profile.

Although I have been injecting Botox since 2009, itwas FDA approved for the treatment of chronic migraine in 2010. Botox does nothave an FDA indication for the treatment of TMD, but I have been injecting forthe treatment of this diagnosis since 2013. Securing a Botox priorauthorization specifically for the treatment of TMD can be challenging. Nearly all of my Botox patients have a priorauthorization for the diagnosis of chronic migraine, and a portion of the Botoxunits are used for the treatment of TMD.

Botoxhas an established action of reducing transmission at the neuromuscularjunction, which makes it a good option for the treatment of overactive muscles thatmay play a role in TMD. It also haseffects on pain signaling. I was pretty amazed at how, for some patients,injecting 20 units in each temporalis and as little as 5 units in each massetercould significantly improve TMD symptoms. With other patients, I have togradually increase the dose by 5 units every visit to doses as high as 40 unitsper side to achieve a benefit. My hypothesis is that lower dose requirementsfor some patients may reflect the responderswho benefit primarily from the effects of Botox on pain signaling, while thoserequiring higher doses may also need the neuromuscular effect of Botox in orderto reduce masticatory hyperactivity. This may explain why patients who aretreated in orofacial pain clinics in general tend to need higher doses, asthese more refractory cases may have a larger motor component to theirTMD.

How often do youtreat TMD in patients with migraine?

Dr Bender: As an orofacial pain specialist, the majority of my practice consists of diagnosing and managing people with TMDs. So, I probably see 6-8 patients per day with some form of a TMD.

If clinicians are overlooking TMD signs and symptoms, the diagnosis will not be made, and an opportunity to treat will be lost.

Dr Mathew: I encounter patients with TMD every single day in clinic, multiple times a day. I would say that if I am performing Botox injections on 15 patients for the treatment of chronic migraine in a day, at least 5 of them are receiving masseter injections for treatment of TMD. TMD is extremely common in my headache medicine practice because I am actively looking for it through my history-taking and examination. If clinicians are overlooking TMD signs and symptoms, the diagnosis will not be made, and an opportunity to treat will be lost.

Whatoutcomes can be expected for comorbid TMD/migraine?

Dr Bender: While every individual will have a unique presentation, if the clinician engages in a comprehensive examination process beyond the traditional neurologic examination and employs evidenced-based therapies for both disorders, outcomes can be very predictable and successful. These therapies are often more comprehensive than the pharmacotherapeutic-based approaches employed by most headache practitioners. Many of our patients with TMDs note a significant improvement in their headache intensity and frequency when their TMD is well-treated.

Dr Mathew: I find the best results occur when patients are on combination treatment with an oral appliance, trigger avoidance, physical therapy with continued self-guided home stretching/exercises, and pharmacological treatment. This is where interdisciplinary collaboration between the neurologist/headache specialist, dentist/orofacial pain specialist, and physical therapist can lead to the best outcomes.

References

1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalagia. dio: 10.1177/0333102417738202

2. The Orofacial Pain Classification Committee. International Classification of Orofacial Pain. Cephalagia. doi: 10.1177/0333102419893823

3. Schiffman E, Ohrbach R, Truelove E, etal. DiagnosticCriteria for Temporomandibular Disorders (DC/TMD) for Clinical and ResearchApplications: recommendations of the International RDC/TMD Consortium Networkand Orofacial Pain Special Interest Group. J Oral Facial Pain Headache. doi:10.11607/jop.1151

4. Kahn A, Kn-Darbois JD, Bertin H, Corre P, Chappard D. Mandibular bone effects of botulinum toxin injections in masticatory muscles in adult. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;129:100-108. doi: 10.1016/j.oooo.2019.03.007. Abstract.

5. Carlson CR, Bertrand PM, Ehrlich AD, Maxwell AW, Burton RG. Physical self-regulation training for the management of temporomandibular disorders. J Orofac Pain. 2001 Winter;15:47-55. Abstract.

View post:
Experts Weigh in on Evaluating, Treating Comorbid Migraine and Temporomandibular Dysfunction - Neurology Advisor

Neurological symptoms of COVID-19: What we know and dont know – WKRN News 2

NASHVILLE, Tenn. (WKRN) Early on in the COVID-19 pandemic; fever, cough, and shortness of breath were the main symptomsassociated with the virus. But as scientists learn more about COVID-19, neurological symptoms are becoming more apparent.

We spoke to Dane Chetkovich, MD, PhD, and Chairman of Neurology at Vanderbilt University Medical Center about the neurological symptoms of COVID-19.

Pretty much any aspect of the nervous system can be affected by the virus or the bodys immune response to the virus. So that goes for muscles, nerves, and the brain itself. An early neurological symptom that was recognized pretty early on was the loss of smell.

Research on these neurological symptoms is ongoing. These symptoms range from mild, like the loss of smell, to severe.

According to Chetkovich, doctors have small numbers of patients who have strokes and who have whats called Guillain-Barr syndrome. Its a nerve disorder that causes weakness and can be very serious.

Many of those with severe cases of COVID-19 have to be intubated or ventilated. Dr. Chetkovich tells us that the longer someone is ventilated the more likely they are to have neurological complications.

The longer that you are in the ICU, the longer that you are on a breathing machine, the more likely you are to have things like cognitive impairment or nerve or muscle damage.

While scientists and doctors learn more about the virus that causes COVID-19 every day, there is still a lot to be discovered. Until a vaccine is ready, the best way to prevent the spread of COVID-19 is to continue with social distancing measures and hand washing.

Stay with News 2 for continuing coverage of the COVID-19 Pandemic.

You can also find more information and resources below:

See the original post:
Neurological symptoms of COVID-19: What we know and dont know - WKRN News 2

Here’s the new neurological coronavirus symptoms found in patients – TweakTown

Scientists have recently conducted studies examining the presence of neurological symptoms in COVID-19 patients.

According to The Next Web, some case reports on COVID-19 patients have found a link between neurological symptoms and the virus. These reports describe the COVID-19 patients experiencing what is called Guillain-Barre syndrome, which is a neurological disorder where the immune system responds to an infection but ends up attacking the body's nerve cells that end up causing muscle weakness, and in some cases paralysis.

Other studies on patients found that some patients were even experiencing COVID-19 encephalitis, which is brain inflammation and swelling. According to larger studies from China and France, 36% of patients have some form of neurological symptoms. These symptoms were mild and included things such as headaches or dizziness, which could be a result of the immune response. These neurological symptoms were more prevalent in serve cases of COVID-19, and included disorientation, inattention, and movement disorders.

ABOUT THE AUTHOR - Jak Connor

Jak's love for technology, and, more specifically, PC gaming, began at 10 years old. It was the day his dad showed him how to play Age of Empires on an old Compaq PC. Ever since that day, Jak fell in love with games and the progression of the technology industry in all its forms. Instead of typical FPS, Jak holds a very special spot in his heart for RTS games.

Go here to see the original:
Here's the new neurological coronavirus symptoms found in patients - TweakTown

Some COVID-19 patients forget where they are, what year it is – ARY NEWS

WASHINGTON: A pattern is emerging among COVID-19 patients arriving at hospitals in New York: Beyond fever, cough and shortness of breath, some are deeply disoriented to the point of not knowing where they are or what year it is.

At times this is linked to low oxygen levels in their blood, but in certain patients the confusion appears disproportionate to how their lungs are faring.

Jennifer Frontera, a neurologist at NYU Langone Brooklyn hospital seeing these patients, told AFP the findings were raising concerns about the impact of the coronavirus on the brain and nervous system.

By now, most people are familiar with the respiratory hallmarks of the COVID-19 disease that has infected more than 2.2 million people around the world.

But more unusual signs are surfacing in new reports from the frontlines.

A study published in the Journal of the American Medical Association last week found 36.4 percent of 214 Chinese patients had neurological symptoms ranging from loss of smell and nerve pain, to seizures and strokes.

A paper in the New England Journal of Medicine this week examining 58 patients in Strasbourg, France found that more than half were confused or agitated, with brain imaging suggesting inflammation.

Youve been hearing that this is a breathing problem, but it also affects what we most care about, the brain, S Andrew Josephson, chair of the neurology department at the University of California, San Francisco told AFP.

If you become confused, if youre having problems thinking, those are reasons to seek medical attention, he added.

The old mantra of Dont come in unless youre short of breath probably doesnt apply anymore.

Viruses and the brain

It isnt completely surprising to scientists that SARS-CoV-2 might impact the brain and nervous system, since this has been documented in other viruses, including HIV, which can cause cognitive decline if untreated.

Viruses affect the brain in one of two main ways, explained Michel Toledano, a neurologist at Mayo Clinic in Minnesota.

One is by triggering an abnormal immune response known as a cytokine storm that causes inflammation of the brain called autoimmune encephalitis.

The second is direct infection of the brain, called viral encephalitis.

How might this happen?

The brain is protected by something called the blood-brain-barrier, which blocks foreign substances but could be breached if compromised.

However, since loss of smell is a common symptom of the coronavirus, some have hypothesized the nose might be the pathway to the brain.

This remains unproven and the theory is somewhat undermined by the fact that many patients experiencing anosmia dont go on to have severe neurological symptoms.

In the case of the novel coronavirus, doctors believe based on the current evidence the neurological impacts are more likely the result of overactive immune response rather than brain invasion.

To prove the latter even happens, the virus must be detected in cerebrospinal fluid.

This has been documented once, in a 24-year-old Japanese man whose case was published in the International Journal of Infectious Disease.

The man developed confusion and seizures, and imaging showed his brain was inflamed. But since this is the only known case so far, and the virus test hasnt yet been validated for spinal fluid, scientists remain cautious.

More research needed

All of this emphasizes the need for more research.

Frontera, who is also a professor at NYU School of Medicine, is part of an international collaborative research project to standardize data collection.

Her team is documenting striking cases including seizures in COVID-19 patients with no prior history of the episodes, and unique new patterns of tiny brain hemorrhages.

One startling finding concerns the case of a man in his fifties whose white matter the parts of the brain that connect brain cells to each other was so severely damaged it would basically render him in a state of profound brain damage, she said.

The doctors are stumped and want to tap his spinal fluid for a sample.

Brain imaging and spinal taps are difficult to perform on patients on ventilators, and since most die, the full extent of neurologic injury isnt yet known.

But neurologists are being called out for the minority of patients who survive being on a ventilator.

Were seeing a lot of consults of patients presenting in confusional states, Rohan Arora, a neurologist at the Long Island Jewish Forest Hills hospital told AFP, saying that describes more than 40 percent of recovered virus patients.

Its not yet known whether the impairment is long term, and being in the ICU itself can be a disorienting experience as a result of factors including strong medications.

But returning to normal appears to be taking longer than for people who suffer heart failure or stroke, added Arora.

comments

Follow this link:
Some COVID-19 patients forget where they are, what year it is - ARY NEWS

It’s not just lungs: Covid-19 may damage the heart, brain, and kidneys – The Daily Briefing

It's widely known that the new coronavirus attacks patients' lungs, but clinicians and researchers around the world are reporting that the virus is damaging other organs, as wella discovery that could have implications for the way doctors treat Covid-19, the disease caused by the virus, and for how patients recover.

Your top resources for Covid-19 readiness

In addition to the widely reported lung injuries associated with Covid-19, clinicians around the world are reporting that the disease also could be causing cardiac injuries in patients that sometimes lead to cardiac arrest.

According to the Washington Post, health care workers in China and New York have reported seeing myocarditis, an inflammation of the heart muscle, as well as irregular heart rhythms in Covid-19 patientseven in patients with no pre-existing heart conditions.

At first, the patients "seem to be doing really well as far as respiratory status goes," said Mitchell Elkind, a neurologist at Columbia University and president-elect of the American Heart Association (AHA). But the patients "suddenly develop a cardiac issue that seems out of proportion to their respiratory issues," Elkind said.

Elkind noted that one review found about 40% of seriously ill Covid-19 patients in China experienced arrhythmias and 20% experienced other cardiac injuries. "There is some concern that some of it may be due to direct influence of the virus," Elkind said.

A separate study of 416 hospitalized Covid-19 patients in China found that 19% showed signs of heart damage, and those patients were more likely to die. According to the study, 51% of patients with heart damage died, compared with 4.5% of patients who showed no signs of cardiac injury.

Doctors are trying to determine whether the damage to patients' heart muscles is caused by the new coronavirus, itself, or if the damage occurs as a result of other symptoms of Covid-19, such as pneumonia and inflammation, Kaiser Health News (KHN) reports.

"It's extremely important to answer [that] question," said Ulrich Jorde, head of heart failure, cardiac transplantation, and mechanical circulatory support for Montefiore Health System. "This may save many lives in the end."

Doctors also are reporting a growing number of Covid-19 patients with symptoms of neurological damage, including brain inflammation, seizures, and hallucinations, the Wall Street Journal reports.

A group of Chinese doctors in a study published last week in JAMA Neurology found that more than one-third of 214 hospitalized Covid-19 patients in Wuhan had neurologic symptoms, the most common of which were dizziness, headaches, impaired consciousness, loss of taste and smell, and skeletal-muscle injuries. More serious but less commonly reported symptoms included seizures and stroke, according to the study.

The findings have prompted doctors to begin performing simple neurological exams on Covid-19 patients, the Journal reports.

Further, while health experts originally were telling patients to avoid seeking care at hospitals unless they had common Covid-19 symptoms such as a fever, cough, or trouble breathing, neurologists are hoping the new data will add neurological symptomssuch as confusion, numbness, or trouble speakingto that list. "This article should open up everyone's eyes that this disorder affects the brain as well." said S. Andrew Josephson, chair of neurology at the University of California-San Francisco.

Kidney damage also is becoming a commonly reported issue among Covid-19 patients.

Alan Kliger, a nephrologist at the Yale School of Medicine, said early data showed 14%to 30%of ICU Covid-19 patients in New York and Wuhan, China, lost kidney function and later required dialysis. Similarly, a study published last week in the journal Kidney International found that nine of 26 people who died of Covid-19 in Wuhan had acute kidney injuries, and seven had units of the new coronavirus in their kidneys.

The findings suggest it's "very possible that the virus attaches to the kidney cells and attacks them," Kliger said.

The new coronavirus also appears to produce blood clots that can travel from patients' veins to their lungs, causing a pulmonary embolism, and other organs.

According to STAT News, Chinese researchers in one report said they found small blood clots in about 70% of the patients who died of Covid-19 and were included in the study. In comparison, the researchers found similar blood clots in fewer than one in 100 patients who survived the disease. In a separate peer-reviewed study of 81 patients in Wuhan that was published last week in the Journal of Thrombosis and Hemostasis, researchers wrote that 20 patients experienced pulmonary embolism and eight died from the condition.

Based on what they've seen so far, doctors said the blood clots in Covid-19 patients are smaller but cause more damage than blood clots typically seen in patients with other conditions, STAT News reports.

Sanjum Sethi, an interventional cardiologist and assistant professor of medicine at Columbia University's Irving Medical Center, said doctors have been using blood thinners to treat the clots in Covid-19 patients, hoping that relieving the clots will allow the patients' immune systems to focus on fighting off the coronavirus.

While Clyde Yancy, chief of cardiology at Northwestern University Feinberg School of Medicine, said it's too early to "declare anything definitively," he added, "[W]e know from the best available data that about one-third of patients who have Covid-19 infections do in fact have evidence of thrombotic disease."

Doctors said it is still unclear why the clots develop in Covid-19 patients, according to STAT News.

While doctors' reports of different types of organ damage in Covid-19 patients are increasing, clinicians and researchers have yet to determine whether the new coronavirus is directly attacking those organs, or whether the injuries are caused by the patients' immune responses to the infection. Doctors said researchers also should investigate whether the organ damage and failure is being caused by medication, respiratory distress, fevers, the stress of hospitalization, and so-called "cytokine storms."

Regardless of the cause, the organ damage is threatening patients' lives. "It's not necessarily the virus killing people, it's the organ failure that happens as a result of the viral infection," said Christopher Barrett, a senior surgical resident at Beth Israel Deaconess Medical Center.

But results indicating that the virus is directly attacking patients' organs could impact the way doctors treat and evaluate Covid-19 patients, especially in the early stages of infection, KHN reports.

"This is a real-time learning experience," Yancy said (Bernstein et al., Washington Post, 4/15; Hawryluk, Kaiser Health News, 4/6; Hernandez, Wall Street Journal, 4/14; Cooney, STAT News, 4/16; Owermohle/Eisenberg, Politico, 4/15).

Go here to see the original:
It's not just lungs: Covid-19 may damage the heart, brain, and kidneys - The Daily Briefing

Her father’s delirium was a first sign of coronavirus. He’s not the only one. – NBC News

Nicole Hutcherson first noticed something was wrong with her father normally a spry early-riser who enjoyed yard work and home renovation projects earlier this month, when he wasn't getting out of bed until nearly midday.

Her dad, Frank M. Carter, 82, of Goodlettsville, Tennessee, insisted he felt fine, despite some nausea and vomiting. Hutcherson suspected he was dehydrated, so she went to his house to give him intravenous fluids. Hutcherson is a nurse, and had supplies on hand.

Full coverage of the coronavirus outbreak

That was when she noticed her father, who had shown no previous signs of dementia, was largely unaware of what was happening around him.

"He looked distant," Hutcherson recalled. "He just had this weird look in his eye, like his mental status had changed."

Carter didn't react at all when his daughter put the IV needle in his arm. "It was like he was sedated," she said.

Hutcherson believes that the delirium she noted in her father was one of the first signs that he had been infected with the coronavirus. Carter died within a week.

There is growing evidence to suggest that COVID-19, the illness caused by the coronavirus, can affect not only the lungs, but the brain, too.

A recent study of 214 patients in Wuhan, China, where the pandemic started, found more than a third had neurologic manifestations of the disease, including loss of consciousness and stroke.

Physicians in the U.S. have noted the same.

"We're seeing a significant increase in the number of patients with large strokes," Dr. Johanna Fifi, associate director of the cerebrovascular center at the Mount Sinai Health System in New York City, said.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

Many are patients in their 30s and 40s. Over a recent two-week period, Fifi told NBC News she had five COVID-19 patients under age 49, all with strokes resulting from a blockage in one of the major blood vessels leading to the brain.

Download the NBC News app for full coverage of the coronavirus outbreak

Two of those patients had what Fifi described as mild coronavirus conditions before the stroke. The other three had no symptoms at all.

How the virus might lead to a stroke or other neurological impairment remains unclear. Fifi said it's possible that inflammation in the body could damage blood vessels in the brain, or that the viral infection leads to increased clotting.

"I don't think we know right now which one it is," she said.

Dr. E. Wesley Ely, a professor of medicine and critical care at Vanderbilt University Medical Center, has another theory: that the virus is "probably invading the brain."

Ely explained that symptoms such as loss of smell and taste reported among some coronavirus patients are neurologic in nature.

"This virus goes into your nose, and says, 'I'm just going to attack the first thing I see.' That's the respiratory tract," Ely said. But because humans have no immunity to this new virus, it's possible that it can attack any part of the body, including the brain.

"That's something that still needs to be teased apart and figured out," Dr. Felicia Chow, an assistant professor of neurology at the University of California, San Francisco, said.

But the issues surrounding loss of taste and smell "make us highly suspicious that ... the cranial nerves may be affected by the virus," she said. "We just don't have any direct proof at this point."

To fill that void, Ely and colleagues with the Critical Illness, Brain Dysfunction and Survivorship Center, in partnership with Vanderbilt and the Nashville VA, have launched a study of post-mortem brain tissue to look for signs of COVID-19 in the brain. The National Institutes of Health is funding the research.

The team will examine the brains' neurons for damage, measure various brain regions to see if parts have become unusually small, and analyze the hippocampus, which plays a large role in memory. They'll also look for evidence of amyloid and tau, two proteins linked to dementia and Alzheimer's disease.

"Anything we find is important because we're trying to understand the pathophysiology of this disease," Ely said.

The first brain donated to the project was Frank M. Carter's.

"My father would have wanted to do this because he was selfless," Hutcherson said. "He would have wanted to help others."

Hutcherson urged others to watch for unusual cognitive changes in family members, including lapses in consciousness and unexplained confusion. It is unknown whether Carter had suffered a COVID-19-related stroke.

Chow added that awareness of other stroke symptoms is also critical, including "drooping of the face, weakness of the arm or leg, especially on one side, and difficulties either understanding or producing speech."

"Those are definitely symptoms of a potential stroke and a reason to immediately call 911," whether they're related to COVID-19 or not, Chow said.

Delaying care can have devastating consequences. "One of our patients waited over a day at home, getting progressively weaker," Fifi, of Mount Sinai Health System, said. The patient told physicians she'd been afraid to go to the hospital because of the coronavirus outbreak.

"If you're having symptoms, it's safer to be in the hospital," Fifi said.

"If you don't re-establish blood flow quickly, the brain becomes irreversibly damaged. The sooner you do it, the better."

Follow NBC HEALTH on Twitter & Facebook.

The rest is here:
Her father's delirium was a first sign of coronavirus. He's not the only one. - NBC News

COVID-19 Linked to Changes to the Brains of Some Sufferers, Scientists Warn – Newsweek

The coronavirus has been linked to brain dysfunction in patients with severe COVID-19, according to research.

The research letter published in the New England Journal of Medicine involved a small sample of 58 COVID-19 patients treated at two intensive care units (ICUs) at France's Strasbourg University Hospital between March 3 and April 3, 2020.

The participantswho were aged 63 on averagehad acute respiratory distress syndrome (ARDS), a life-threatening complication of COVID-19 where the lungs are unable to provide the vital organs with sufficient levels of oxygen.

Seven of the participants had neurological disorders in the past, including a mini-stroke, partial epilepsy and mild cognitive impairment.

Of the total patients, eight had experienced some form of neurological problem before they were hospitalized, and 39 when sedation and muscle relaxants were withheld. Forty patients became agitated when muscle relaxants were discontinued, and a further 26 experienced confusion, according to a measure used by the team.

In 39 patients, problems with a part of the brain involved in movement were reflected in involuntary muscle spasms on the ankle, "enhanced tendon reflexes" and their toes fanning instead of curling when given a reflex test.

When the authors wrote their letter, 15 of the 45 patients who had been discharged had what is known as dysexecutive syndrome, where their executive functions were disrupted. They felt either disorientated or found it hard to follow commands when asked to make certain movements.

The clinicians performed MRI brain scans on 13 patients, and found abnormalities including inflammation of the lining of the brain and breakdown of the normally tight blood-brain-barrier in eight, and a loss of blood flow in all 11 who had a special type of imaging. Two asymptomatic patients had mini-strokes, the authors said.

The team said it was not clear whether the patients had these problems because of the coronavirus itself, the body's response to infection, or the effect and or withdrawal of medication.

Professor Cris S. Constantinescu of the Division of Clinical Neuroscience at the U.K.'s University of Nottingham Queen's Medical Centre, who did not work on the article, told Newsweek the research "shows that a substantial proportion of people with severe COVID-19 leading to ARDS have neurological problems."

Constantinescu pointed out the issues mostly affected the entirety of patients' brains, and were non-localizing. This indicates that the dysfunction cannot be traced to a specific side or part of the brain.

The letter "adds to the evidence of neurological manifestations of COVID-19 and suggests that those who recover need to be monitored for neurological abnormalities, including possible cognitive deficits. This will also determine whether the deficits reported here are transient," he said.

However, Constantinescu added: "Although this series is substantial, it is limited to severe cases who develop ARDS and are admitted to intensive care.

"Some of the aspects may not be COVID-19 specific, as ARDS of other causes, intensive care stays, and sedation all can contribute to encephalopathic features."

Constantinescu concluded: "Longer-term follow-up studies in people who recover after COVID-19 of various levels of severity will be important."

The letter comes as experts learn about the characteristics of COVID-19 disease caused by the new coronavirus, which was first identified in the Chinese city of Wuhan late last year. According to Johns Hopkins University, more than two million COVID-19 cases have been confirmed, almost 138,500 people have died, and more than 525,800 are known to have survived. As the Statista below shows, the U.S. is the hardest-hit country in terms of cases.

On Monday, a separate team of researchers at the University of California San Diego asked whether we are facing a "crashing wave" of neuropsychiatric conditions linked to COVID-19 in a pre-proof article published in the journal Brain, Behavior, and Immunity.

Neuropsychiatric conditions are mental illnesses linked to disease affecting the nervous system, and can range from depression and anxiety to addictions and seizures. They wrote that "the COVID-19 pandemic is a significant source of psychological distress globally." What's more, the virus itself and the immune responses it triggers "may also directly affect brain and behavior." Past pandemics have been linked to neuropsychiatric conditions, they said.

"COVID-19 is projected to affect a remarkably high proportion of the global population, which is unprecedented for a virus with such case fatality and infection rates in modern medicine. Nevertheless, the neuropsychiatric burden of this pandemic is currently unknown, but likely to be significant," the team wrote.

Earlier this month, doctors reported what was thought to be the first known case of a person experiencing brain damage linked to COVID-19 in the journal Radiology.

Hygiene advice

Medical advice

Mask and glove usage

Read more

Read the original post:
COVID-19 Linked to Changes to the Brains of Some Sufferers, Scientists Warn - Newsweek

Coronavirus long-term health: COVID-19 impact on lungs, heart, kidneys, brain – TODAY

As more people recover from COVID-19, some will find their ordeal may not end when the infection is over.

With the disease emerging in China a few months ago, doctors are just starting to get a better understanding of how the new coronavirus impacts long-term health.

For now, it appears most patients who have had mild symptoms can expect no lasting harm, experts said.

For the vast majority of people who get the coronavirus, theyre not going to have any long-term consequences for it, Dr. Amesh Adalja, a senior scholar at the Johns Hopkins University Center for Health Security in Baltimore and a spokesman for the Infectious Diseases Society of America, told TODAY.

Its going to be like a cold or a flu and they go about their lives once they recover in a week or two from it.

But survivors of the severe type of the illness may face a much more complicated picture, and not just when it comes to their lungs.

COVID-19 seems to be more than a respiratory disorder, with people also experiencing a gastrointestinal version of the disease.

Doctors are also trying to figure out any long-term impact on the heart and other organs, said Dr. Andrew Freeman, a cardiologist at National Jewish Health in Denver, Colorado, and a member of the American College of Cardiologys COVID-19 Response Work Group.

Were going to see enormous populations of people who have convalesced who have survived the virus. Then the question is: Do we need to give them echocardiograms? Do we need to do other things to surveil for whatever the long-term (consequences) are? Freeman said.

"I dont think we know the answers to those questions yet."

Heres what doctors have seen so far:

COVID-19 patients who developed acute respiratory distress syndrome a life-threatening lung injury due to infection and had to be hospitalized in the intensive care unit are more likely to have long-term consequences, Adalja said.

There are people who are going to have scarring in their lungs from whats happened and that may not be completely reversible, he noted. Its not just with coronavirus; we see this with all types of pneumonia that lead to ARDS.

Trending stories,celebrity news and all the best of TODAY.

These patients may have diminished lung function thats going to persist, including decreased exercise capacity that leaves them short of breath.

Some COVID-19 survivors had a 20-30% drop in lung function after recovery and gasp if they walk a bit more quickly, doctors in Hong Kong told the South China Morning Post last month.

In such cases, cardiopulmonary rehab may help in rebuilding strength and capacity, though a person may not return completely all the way back to baseline, Adalja said.

About 20% of patients with COVID-19 in China had heart damage during hospitalization, a recent study found.

Another study discovered about 16% patients developed arrhythmia, while other reports indicated cases of acute onset heart failure, heart attack and cardiac arrest after coronavirus infection, the American College of Cardiology warned.

People with the severe form of the illness can also develop myocarditis, an inflammation of the heart muscle, and sometimes dont fully recover by the time theyre discharged from the hospital, Freeman noted. Its possible this condition could persist in some way.

Whenever theres enormous demand placed on the heart in cases when someone is severely sick and on life support, for example, or dealing with an intense inflammatory response there can always be some element of cardiac injury, he explained.

Plus, any long-term lung disease can have effects on the heart, particularly its right side.

The lungs and heart are coupled tightly, Freeman explained. Sometimes when the lungs are ill, the pulmonary arteries which are what leaves the right side of the heart can also develop inflammation, disease or a thickening.

In addition, viral illnesses can destabilize plaque in the arteries, potentially resulting in a blockage and putting patients at risk of a heart attack, the American Heart Association warned.

Theres no evidence COVID-19 hurts the kidneys of people who have mild to moderate infection, but kidney abnormalities have been seen in 25-50% of patients who develop the severe type of the disease, according to the International Society of Nephrology.

Those patients have more protein and red blood cells in their urine. About 15% of them also develop a decline in filtration function.

The new coronavirus is an infectious organism and can lead to a cascade of immune changes that lead to sepsis, and sepsis is characterized by multiple organ systems being compromised, Adalja said. Some individuals with sepsis can get acute kidney injury.

The long-term health effect of this on COVID-19 survivors is not known, the organization noted.

The longer patients have to remain in the ICU, the more likely they are to suffer long-term cognitive and emotional effects of being sedated. Doctors call it "post-intensive care syndrome" or post-ICU delirium, and describe it as a type of post-traumatic stress.

"Often when patients come out of the ICU, they really struggle to think as clearly as they did before," Dr. Amy Bellinghausen, a pulmonary, critical care and sleep medicine fellow at the University of California, San Diego, told NBC News.

She estimated up to two-thirds of ventilated patients may be affected. Possible causes include not getting enough oxygen or blood to the brain, or the medications used to sedate a patient.

Neurologic symptoms may be possible, too. Other coronaviruses that affect humans can invade the central nervous system, so it makes sense COVID-19 may have neurologic manifestations, Dr. Kenneth Tyler, chair of neurology at University of Colorado School of Medicine in Aurora, told Neurology Today.

Indeed, a study published Friday found neurologic symptoms were seen in 36% of 214 COVID-19 patients in China, including dizziness, headache and taste and smell impairment. It's not clear how long they last.

Bottom line: Doctors are still trying to understand any effects that are unique to the new coronavirus.

There may be some differences in the way the immune system reacts to this (virus), Adalja said. Well only learn that from long-term studies of survivors.

Here is the original post:
Coronavirus long-term health: COVID-19 impact on lungs, heart, kidneys, brain - TODAY

American Neurological Association Hosts First-Ever All-Virtual Annual Meeting – PRNewswire

MOUNT LAUREL, N.J., Sept. 3, 2020 /PRNewswire/ --On October 4-9, 2020, the American Neurological Association, for the first time in its 145-year history, is moving from a traditional meeting format to an interactive, virtual meeting experience. As always, the meeting will explore the latest advances in translational neuroscience, neurobiology of disease and academic neurology. In addition, ANA has announced that it is giving back to the neurological community by providing members with complimentary registration for ANA2020 and significantly reduced registration rates for non-members.

"We recognize that these are unprecedented times, and we are committed to providing meeting access to neurologists and neuroscientists around the world," explained ANA's Executive Director Nadine Goldberg, PhD, MS. "For over 100 years, we have brought together the best researchers and educators in this field, and this year will be no different in that respect, as we transition to an interactive, virtual event." She noted that it is important that all attendees register for the meeting in advance.

Many sessions held during the meeting will be pre-recorded, with live, interactive Q&A sessions following.This year's symposia dives into the science behind recent breakthroughs in our understanding and treatment of neurological disorders across a broad etiological spectrum and will feature talks and poster presentations with latest advances in translational neuroscience, neurobiology of disease, and academic neurology. The four plenary sessions are:

Also, on the schedule are 18 Special Interest Group (SIG) sessions, including Global Neurology, Traumatic Brain Injury, and Neurogenetics. New this year is the Emerging Scholar Lecture series, which is focused on providing junior investigators a platform to discuss their work. In addition, the Derek Denny-Brown Young Neurological Scholar Symposium will feature presentations from the 2020 Derek Denny-Brown awardees, the Wolfe Neuropathy Research Prize and the Grass Foundation-ANA Award in Neuroscience recipients.

ANA Social Justice Symposium to Address Inclusion and Diversity

The ANA is challenging itself to become a champion of 21st century academic neurology and neuroscience. Given that its past was marred by systemic racism, the ANA is working hard to find new ways to rectify these exclusionary practices. To meet these challenges, ANA is redoubling its efforts around inclusion and diversity through educating the neurological community and implementing organizational changes. In line with these efforts, the ANA is hosting its inaugural Social Justice Symposium prior to ANA2020. During this symposium attendees will learn about topics ranging from the impact of social determinants of health on adverse health outcomes for people of color, health policy, and will participate in interactive breakout sessions designed to develop actionable steps to address inequity within academic neurology and neuroscience.

A detailed Advance Program is online at https://2020.myana.org

Follow the meeting live using #ANA2020 on Twitter @TheNewANA1, on Facebook @AmericanNeurologicalAssociation, or on Instagram @ananeurology.

ABOUT THE ANA

The American Neurological Association is a professional society of academic neurologists and neuroscientists devoted to advancing the goals of academic neurology; to training and educating neurologists and other physicians in the neurologic sciences; and to expanding both our understanding of diseases of the nervous system and our ability to treat them.

For more information, visit http://www.myana.org or follow @TheNewANA1 on Twitter, @AmericanNeurologicalAssociation on Facebook, or @ananeurology on Instagram.

SOURCE American Neurological Association

https://2020.myana.org

Continued here:
American Neurological Association Hosts First-Ever All-Virtual Annual Meeting - PRNewswire

Susan Griffith DO | Doylestown Health

Certifications

Orthopedic Surgery

Medical School: Philadelphia College of Osteopathic Medicine

Residency: Frankford Hospital-Bucks County Campus, Alfred I. DuPont Hospital for Children, Phila. College of Osteopathic Medicine, The Cooper Hospital

Fellowship: St. Christopher's Hospital for Children, Shriner's Hospital for Children

Female

English

Dr. Susan Griffith specializes in pediatric orthopedics. She has trained extensively in her field and holds a Master's degree in Biomedical Sciences from the Philadelphia College of Osteopathic Medicine, where she earned her Doctorate in Osteopathic Medicine. She completed an internship at Frankford Hospital in Langhorne, Pa.

Dr. Griffith successfully undertook her residency at Frankford Hospital and Philadelphia College of Osteopathic Medicine. She rotated through: trauma (Cooper Hospital in Camden, New Jersey); pediatric orthopedics (A.I. DuPont Hospital for Children in Wilmington, Delaware); orthopedic surgery (Frankford Hospital-Bucks and PCOM); Graduate Hospital and Rothman Institute for Shoulder and Elbow. Dr. Griffith completed a prestigious fellowship in pediatric orthopedics at two Philadelphia institutions: Shriner's Hospital for Children and St. Christopher's Hospital for Children.

Dr. Griffith is board certified in orthopedic surgery and holds professional membership in a number of organizations, including the American Osteopathic Association, the American Osteopathic Academy of Orthopedics, where she served as chairman of pediatric orthopedics in 2006, and the Female Orthopedic Group. Dr. Griffith was honored with the American Osteopathic Academy of Orthopedics Fellowship Award in 2007.

Dr. Griffith has presented at numerous professional meetings and symposiums. Her research projects include Fracture Incidence in Breastfed versus Bottlefed Children and Catastrophic Injuries in Cheerleaders.

Go here to see the original:
Susan Griffith DO | Doylestown Health

The Emotional Toll: How These Neurology Departments Are… : Neurology Today – LWW Journals

Article In Brief

Virtual happy hours, town hall meetings, and email blasts are some of the ways medical teams across the country are managing their patients amid the COVID19 outbreak.

As of April 13, about a third of the residents at NYU Langone Health14 individualshad established COVID-19 or symptoms, although not formally tested.

They were just sent home assuming they had COVID-19 until their symptoms abated and they were afebrile for three days, said Steven L. Galetta, MD, FAAN, professor and chair of neurology. A few attendings had also fallen ill. Everyone in the neurology department was working from home unless they were needed for inpatient care or part of a skeleton crew conducting urgently needed outpatient care that could not be handled via telemedicine. At least 80 percent of hospitalized patients were being treated for COVID-19.

As the pandemic bore down on New York City, Dr. Galetta quickly grasped that he needed to address the emotional toll of the crisis. People are exhausted and fear is understandably a big factor in this situation, he said. But we know that we are in this together and that we just have to find a way to do this.

His strategy: Remind everyone in the department they are part of a community. Each neurology division started scheduling weekly virtual happy hours using Zoom, and Dr. Galetta attends as many as possible to stay connected. They last an hour and we usually have 10 to 15 people, generally all attending from the confines of their homes, he said. And we have great conversations about medical and nonmedical aspects of what's happening.

In addition, the department collected money to buy meals to be delivered to their colleagues working in the hospitals. We raised $14,000, as a department, from attendings and other donors, to feed the front linesour neurology residents working on medical units, the advanced care practitioners and other nurses, he said. They don't have time to go to the cafeteria so we supply them and that's a morale builder.

A weekly group counseling session, conducted via Zoom, is being led by several neuropsychiatrists.

Dr. Galetta started sending a daily email to residents and faculty, summarizing the latest informationthe number of COVID-19 cases, the train schedules and whatever else. Each day's note includes a music videoan inspirational song or even a concertand a bit of COVID-19 humorIt's impossible to touch your face if you have a wine glass in each handsent to him by attendings or residents to share with their colleagues. We are trying to balance the reality of this crisis and the sadness of it with other things that are important in life, he said.

As of April 8, Johns Hopkins Medicine was deep into preparation for a COVID-19 surge that everyone hoped would not come. There were 109 COVID-positive patients in the hospital on that day, and several neurology residents had volunteered to be redeployed to the department of medicine if needed. To alleviate the residents' burden, neurology faculty members and fellows were handling all outpatient activities and prepared to take over some of the residents' inpatient work if necessary, said Justin C. McArthur, MD, MPH, FAAN, professor and director of the neurology department.

The residents are stressed and working quite hard, so we have changed the rotations, he said. People basically have six days on, six days off, so they have a block of time away to recoup.

Faculty members were bringing home-cooked food for the residents, and Dr. McArthur was reinforcing the community spirit through weekly department-wide Zoom meetings. Operational information is discussed, followed by a brief concert. The idea came from Alexander Pantelyat, MD, assistant professor of neurology and co-director of the Johns Hopkins Center for Music & Medicine.

He's very well connected with the Baltimore Symphony Orchestra (BSO), which is of course not playing live concerts right now, Dr. McArthur said. So we have lined up a number of the BSO musicians to do these mini-concerts once a week for us.

Meanwhile, another faculty memberSusan Magsamen, executive director of Johns Hopkins' International Arts + Mind Labcompiled educational and arts resources that department members can use with their children during the COVID-19 lockdown.

We are trying to do things to take care of our own, Dr. McArthur said.

His tip for other neurology leaders: Develop a communication strategy that makes it easy for department members to find the information they need. There's a balance between over-communicating and under-communicating, he said. Rather than sending out 20 emails every day, we send out one that is curated and has all of the information in one place.

The department also developed a Wiki-page that archives all information so people don't have to search through lots of email messages to find something they need.

New York City Health and Hospitals Corp. operates 11 public hospitals, including Kings County Hospital in Brooklyn, that on average have a total daily inpatient census of about 3,500 patients. On April 13, those hospitals were treating 3,000 COVID-19 patients, including 950 who were intubated.

I think we all had to come to terms with our own mortality and go through the Kubler-Ross stages of mourning for the loss of our previous state of complacency, said Helen A. Valsamis, MD, chief of neurology for Kings County and professor and vice chair of neurology for SUNY Downstate Medical Center. As physicians and educators, we are particularly stressed because we are on the front lines and responsible for the safety of our residents and fellows.

In an email, Dr. Valsamis said her department has changed its call-duty protocol during the COVID-19 crisis. Because being on clinical services is now more stressful, we now have a daytime attending and our high-risk attendings take night calls from home, she said. That way, the daytime attendings are well-rested and better able to function safely during the day. With the help of our SUNY Downstate colleagues, we set up a telestroke cart that we can use if the residents need additional attending support at night.

Although many hospitals around the country are reporting a lower volume of strokes than usual, Kings County has seen an increase in strokes. For stroke codes, we have created pre-packaged, readily available PPE (personal protective equipment) kits so that the resident can don and go, she said.

Clinicians were trained in how to perform a targeted neurologic exam with minimal patient contact. For the neuro exam, we stopped doing fundoscopic exams and the face shields enable us to evaluate pupils safely, she said. We made copies of the NIHSS (National Institutes of Health Stroke Score) cards that were on letter-size paper. That way the residents can stand farther away while administering the aphasia testing portion of the NIHSS and discard the papers after use.

The Detroit area had more than 21,000 confirmed cases of COVID-19 and 1,340 deaths as of April 13. Detroit Medical Center, the largest health system in the metro area, has attracted national media attention for overwhelmed emergency departments. Jun Li, MD, PhD, professor and chair of neurology at Wayne State University School of Medicine, said the serious shortage of personal protective equipment (PPE) has limited each clinician's use to one mask per day.

In an interview with Neurology Today on April 10, Dr. Li said a few neurology residents have tested positive for COVID-19 and one attending who was infected has recovered. He counsels faculty and residents to focus on reality: the majority of COVID-19 patients experience mild symptoms and recover quickly.

During a crisis, people tend to overreact, Dr. Li said. Everyone should constantly evaluate themselves to differentiate their emotional reaction to the situation from the real risk.

Like most neurology departments, Wayne State has pivoted to telemedicine for the vast majority of outpatient care. While everyone is displaced from their normal work setting and typical routines, Dr. Li wants to limit discombobulation by staying productive.

Keep every attending and resident as busy as possibleotherwise, people feel anxious, he said. I find it is important and quite effective to reduce anxiety and fear by restoring normal activity as much as possible.

To that end, his department is finding ways to implement telemedicine clinics quickly and restore routine educational activities. For example, grand rounds lectures are being conducted through Microsoft Teams technology. When people see normal activities, they feel normal, he said.

Focusing on the future, which will present another challenge, reinforces the reality that the COVID-19 crisis will eventually end. Unable to perform elective procedures for months, health systems are seeing revenues plummet. Dr. Li estimates that outpatient care delivered via telemedicine will save only 30 to 40 percent of his department's budgeted revenue. We have to start thinking about the post-COVID phase now, he said. How are we going to recover financially? All leadership needs to be working together on the plan.

Ronald Reagan UCLA Medical Center had 44 COVID-positive inpatients on April 8, and members of the neurology department at the David Geffen School of Medicine at UCLA were caught between their professional preparations for a possible surge and their personal vulnerability. That is creating a dynamic that has destabilized a lot of health care workers and staff, said S. Thomas Carmichael, MD, PhD, chair and professor of neurology. They feel the obligate healthcare duty to control the safety of their patients as much as possible and at the same time feel an uncontrolled risk to personal infection.

He is using three strategies to keep communication about the fast-changing situation flowing. In addition to a daily staff newsletter, written by Dr. Carmichael and the department's clinical directors, he is scheduling town halls on Zoom. We had 120 participants on this last one, he said. We have a really modest agenda because the main thing is for people just to fire questions and we answer them.

Residents get more attention than ever. I meet with the residents because they are the tip of the spear, he said. I need to make sure that they feel like they're heard and often their ideas are great and presage ideas that we would normally have but a day or two ahead of the rest of us.

The third strategy: Show up for every type of clinical scenario that clinicians and staff are dealing with. I'm in the clinic daily; I'm in the hospital daily; and I respond to emergency situations in the emergency department, he said. It helps me be more effective in revising how our protocols are we move forward. And I think it relieves stress and anxiety when others see me in the middle of it, willing to provide health care right on the front lines.

Tips for his colleagues: Use GoPro technology to allow residents and medical students to learn even when they are not in a patient's room. His department is using a one-plus approach to inpatient care; only an attending and either a resident or fellow go into a patient's room. The resident or fellow wears a GoPro, which beams video in real time to other members of the care team so everyone can see what's happening.

As the COVID-19 surge hit New Jersey on April 8, the neuro-intensive care unit (ICU) at the Robert Wood Johnson University Hospital in New Brunswick became part of the COVID-19 surge plan. Stroke patients who needed critical care services were moved to a separate unit. The neuro-ICU faculty are fully credentialed to take care of patients with acute respiratory distress syndrome and complications of COVID, said Suhayl Dhib-Jalbut, MD, professor and chair of neurology at Rutgers-New Jersey Medical School and Robert Wood Johnson Medical School.

So they are doing bothtaking care of neurological patients with critical conditions and COVID patients, he said. You can imagine that their hours have been stretched.

The long hours that some clinicians are experiencing during the pandemic are one of many stressors that Dr. Dhib-Jalbut is dealing with. His colleagues are worried about being infected with COVID-19 and spreading it to family members who might be vulnerable to COVID complications. They are worried that the health system might be overwhelmed above capacity to deal with COVID-19 patients. Non-essential staff are worried about possible furloughs because outpatient volume has fallen sharply.

Beyond that, clinicians are worried about indemnification. One concern is the possibility of being redeployed to care for patients outside their area of expertise, Dr. Dhib-Jalbut said. Another is the challenge of diagnosing and treating new patients via telemedicine. The department is only accepting new patients if they have an urgent or unique need because, without an in-person examination, it might be difficult to commit to a diagnosis and treatment plan.

Communication and transparency with faculty, with trainees and with staff are going to be key to keep everybody engaged and informed, he said. We are doing many meetings, sometimes daily.

He encourages colleagues to take advantage of counseling hotlines that Rutgers has set up for faculty, staff and students and temporary housing being offered to physicians who live in New York or far away from work. Providing housing arrangements for those faculty who have duties in the hospital is very helpful, he said.

His tip for colleagues: Neurology departments need to pitch in to help their colleagues during a COVID-19 surge. We may be deploying some residents to be part of the Medicine Service team, and to the emergency department so they can be first-responders for patients who present with neurologic symptoms, he said. We know that emergency department physicians are overwhelmed.

At the start of April, Jackson Memorial Hospital in Miami had at least 120 COVID-19 patients and University of Miami Hospital had more than 80 patients who had tested positive and or pending results. Two Jackson Memorial employeesa radiology technician and an intensive care nursehave died from the disease.

We're not at the surge peak but we are getting closer, said Ralph L. Sacco, MD, MS, FAAN, professor and chair of neurology at the Miller School of Medicine at the University of Miami.

The numbers have likely changed since then as is the way the neurology department has had to adapt in the face of COVID-19.

Most faculty members are learning how to conduct outpatient care via telemedicine on the fly and almost everybody is working from home. Sometimes that can increase isolation and it also makes it harder if you have children at home that you're trying to attend to, he said. So stress definitely has gone up in a big way.

Dr. Sacco emphasizes that physical distancing does not require social distancing. We can connect with one another from FaceTime and other ways so we can still see each other, he said, adding that faculty meetings and executive leadership committee meetings, now via Zoom, have been moved up to weekly instead of monthly.

To cope with the anxiety caused by the pandemic, he encourages department members to take advantage of the university's new pandemic counseling service for employees. Anybody can call in and get a virtual visit with a psychologist or psychiatrist, he said.

Meanwhile, a psychologist who has been working to help neurology residents with wellness during their training years has offered to provide group or individual counseling sessions to members of the department during the pandemic.

Tip for his colleagues. Create a three-deep backup list for inpatient care if residents are redeployed to medical units or get sick. We cover a lot of inpatients across two hospitals, so if somebody goes out, we need to have one, two, three deep in terms of coverage, Dr. Sacco said.

For more on how neurology departments have responded to the emotional toll of COVID-19 on their faculty, read more of the stories online: https://bit.ly/COVID-WeillCornell (Weill Cornell) and https://bit.ly/NT-COVID-UCLA (UCLA).

Visit link:
The Emotional Toll: How These Neurology Departments Are... : Neurology Today - LWW Journals

Lakeland firefighter on the road to recovery after battling Guillain-Barr syndrome – WTSP.com

GBS is a rare neurological disorder where the body's immune system mistakenly attacks nerves by your brain and spinal cord.

LAKELAND, Fla. Strong, fighter and hardworking are just a few words fellow Lakeland Fire Department firefighters used to describe fellow first responder Driver Engineer Steve Connors.

Connors is on the road to recovery after he survived "the struggle of a lifetime" since late 2019 when he was diagnosed with Guillain-Barr syndrome, or GBS.

GBS is a rare neurological disorderwhere the body's immune system mistakenly attacks nerves by your brain and spinal cord. It can be mild from brief weakness to "nearly devastating" paralysis.

For Connors, it meant initial unexplainable weakness and tingling in his limbs before developing extreme pain, paralysis and the inability to eat, walk, speak or breathe on his own.

But now, he is on the road to recovery.

"Steve is strong. Steve is a fighter. He is no stranger to hard work," the fire department wrote on Facebook about the former Army soldier and deputy. "He channeled his strength, faith, love and support from his family (fire-family included) and has overcome this hurdle in an extraordinary way!"

Through all of Connors' work and physical therapy, he has relearned how to eat and walk and is working to re-strengthen his body to return to the squad.

The fire department said he let them share his story to help inspire others through there struggles and offer hope in a challenging time.

"Steve allowed us to share his very personal story, so that it can serve to inform and INSPIRE others experiencing their own struggles, whatever they may be.

"This story of #hope and #triumph is exactly what we could all use in these challenging times," the department wrote.

Here is to a speedy recovery Driver Engineer Steve Connors!

What other people are reading right now:

See original here:
Lakeland firefighter on the road to recovery after battling Guillain-Barr syndrome - WTSP.com

COVID And The Brain: ‘You Should Be Afraid’ – KPBS

Horror explores themes relating to the brain be it about disembodied brains on a rampage or how someone can control your mind or what happens to your gray matter when you're zombified. Now COVID-19 is serving up real horrors about how it can affect the brain. UC San Diego Health neurointensivist Dr. Navaz Karanjia explains what the dangers are.

Aired: August 10, 2020 | Transcript

"World War Z" novel by Max Brooks

"The Mind Explained" documentary

"Memento" narrative film about amnesia

Horror frequently explores themes relating to the brain be it about disembodied brains on a rampage or how someone can control your mind or what happens to your gray matter when you're zombified. Now COVID-19 is serving up real horrors about how it can affect the brain. UC San Diego Health neurointensivist Dr. Navaz Karanjia explains what the dangers are.

As someone who is fascinated by how the brain works, I love when pop culture finds creative ways to explore our fears and fascination with an organ that still mystifies us on many levels. This leads me to something else I love, picking the brains of neuroscientists. In this case I spoke with Karanjia about how COVID affects the brain, which is an area of the virus that I have not seen discussed that often.

Karanjia's specialty is neurocrtical care, and the technical term for her position is a neurointensivist, which she said "means I take care of any patient who has a brain problem severe enough to land them in the ICU, so I take care of patients with strokes, seizures, bad brain tumors, brain hemorrhages, brain infections, brain trauma, etc."

How COVID attacks the brain

Now her area of expertise is being tapped as doctors are seeing more neurological complications from the coronavirus.

Karanjia outlines three ways by which COVID can attack the nervous system: "One, by direct viral invasion, coming through the bloodstream or by infecting the nerves in the nose the olfactory nerves that are attached to the brain and crawling along them to the brain. Two, by the body creating antibodies that attack the brain and nervous system. And three, by causing systemic inflammation to the other organs and blood vessels that can cause blood clots to form all over the body, that may get shot up through the heart to the brain, or that may form in the brain itself.

But there are some facts emerging about the virus and the brain.

"The thing that's tragic and fascinating about COVID is it can affect the brain and nerves in so many different ways," Karanjia said. "For example, the damage it causes to blood vessels can lead to strokes and brain hemorrhages in up to 6% of hospitalized patients. Low oxygen levels caused by the lung and heart injury can damage the brain. And the inflammation itself from the infection can affect the brain and the nerves, causing confusion and delirium in the majority of patients with severe COVID. It can also directly affect the nervous system. In mild cases, it can cause loss of taste or smell, or in severe cases it can cause meningitis. We've also seen it cause, an autoimmune reaction, where the body's antibodies to the virus accidentally attack the brain and nerves, and that can cause life threatening issues like brain swelling and Guillain-Barre syndrome."

And finally, there are psychiatric symptoms that are being reported.

"We're seeing people with hallucinations, even psychosis, even after mild COVID disease, which could be from brain involvement," Karanjia said. "One COVID patient in her 50s, with no psychiatric history, with mild symptoms of fever, cough, and loss of taste and smell, was hospitalized for three days requiring minimal oxygen treatment. After discharge her husband reported she was confused and doing strange things like taking her coat on and off repeatedly, and reporting visual hallucinations of monkeys in her house, as well as auditory hallucinations. And then there's the anxiety, depression and PTSD due to the psychological trauma of being hospitalized with a frightening disease."

The neurological problems related to COVID can range from mild like headache or loss of taste and smell, which have been commonly documented in symptomatic patients, to more concerning things like difficulty concentrating or thinking, which has been called brain fog, to confusion and delirium. The virus is creating neurological complications by causing strokes or depriving the brain of oxygen as well as by attacking the brain cells directly.

"So there are plenty of reports of meningitis and encephalitis, or inflammation of the brain, from the virus infecting the brain," Karanjia stated. "We also know that even in minimally symptomatic patients, when they have an MRI, they can demonstrate evidence of inflammation of the brain even if they don't have neurologic symptoms. So the exact number of patients that that are having neuro-invasion is unclear. But because an early symptom of COVID is commonly the loss of smell and taste, which is carried by the nerve from the nose that goes directly to the brain, the olfactory nerve, we are concerned that direct invasion of the neuro-system is happening in a much larger percentage of patients than we would normally expect with a virus like this."

COVID and strokes

The damage a stroke can cause to a patient is something that doctors are familiar with. Karanjia is particularly concerned with how COVID can create these life threatening complications.

"We've seen, strokes from those blood clots I talked about, brain swelling, seizures, coma from infection and inflammation of the brain, paralysis from autoimmune attacks on the nerves, she said. What I'm seeing most commonly is delirium in the very sick COVID patients. And we've seen a number of strokes as well, both of which can have permanent consequences. Although they happen more frequently, the more severe the patients COVID symptoms, it's important to note that these neuroemergencies can even happen to patients with mild respiratory symptoms. We've seen some young patients with minimally symptomatic covid with no stroke risk factors come in with devastating large strokes."

Karanjia wants people to be aware of the symptoms that signal a stroke be it from COVID or from other health reasons.

"One of the ways to remember the symptoms of stroke is the mnemonic BE FAST," she explained. "B for sudden balance problems. E for sudden eye or visual problems. F for facial drooping. A for arm weakness. S for speech problems. And T is time to call 911 because we have excellent treatments for stroke that can return up to 70% of patients back to a functional life, but they only work if they're started within hours of symptom onset 2 million neurons are dying every minute you're having a stroke. So that's why it's so important to call 911 immediately. And that's not an exhaustive list of all the symptoms that could be indicative of neuro complications. If you see somebody convulsing, confused, sleepier than usual, with a bluish tinge to their face, or just generally not acting like their normal self. Call 911."

But Karanjia also wants to point out that there are effective treatments for some of the side effects COVID is causing.

There are a number of promising medications under investigation. But of course, the best treatment will be to prevent getting it in the first place, Karanjia said. We already have excellent treatments for stroke. For example, we have clot busting drugs and procedures to remove brain clots that can return folks to a functional life up to 70% of the time as long as they reach the hospital within hours of their symptoms. And we also have excellent neurocritical care treatments for the other conditions.

Long term effects of COVID

Again, since coronavirus is a novel strain that doctors and scientists have not seen before, there is no way to know what the long-term effects of the disease might be. So even if you have recovered from the obvious symptoms of COVID you may have lingering problems for an as yet unknown length of time.

"On MRI, some patients with no symptoms except for loss of smell have brain inflammation. And for some of those patients, their symptoms are still ongoing. So we don't know how long they will last or what percentage of people will get them or whether there are other long term effects. That's why there are studies going on to investigate those long term effects," Karanjia said.

One of the unique things about COVID is the effect it has on the blood vessel lining that causes clots everywhere in the body.

This is not something we've seen from common viruses before, and that's why the effects of COVID seem to be more devastating and causing more widespread organ damage than we're used to seeing with other viruses," Karanjia said. "In addition to the specific effects of COVID, we are also concerned about the number of patients that may develop Post Intensive Care Syndrome, or PICS, which can cause memory and thinking problems similar to Alzheimers Disease, psychiatric problems like PTSD, and physical problems like ongoing fatigue and weakness. Up to 50% of patients that survive an ICU stay can develop PICS. PICS clinics and COVID neuro clinics are now opening around the country to help patients with these long term effects."

What being a novel coronavirus means

COVID-19 is a novel coronavirus and that means scientists have only been able to study it since it was first discovered late last year. That also means new information is continually being discovered as studies evolve with more patients over more time.

"Any new disease is a challenge because there's limited data at first," Karanjia explained. "It takes years to design studies, recruit patients and perform the study in a scientifically rigorous and ethical way. But now you've got a highly infectious disease that progresses rapidly over days to weeks. The longer-term effects will take time to discover. So, for example, during the Spanish flu pandemic of the early 20th century, nobody knew what the effects would be on babies. So we needed decades of follow up to discover what those effects were."

But with the Internet, social media, and the politicizing of the pandemic there is a lot of misinformation and changing information that can be difficult for people to filter through. A similar situation occurred during the Spanish flu.

Unfortunately, during the Spanish flu pandemic, for example, people were also desperate, she said. Some were hawking quinine as a treatment, which it's not for the flu, and protesting against mandatory mask laws then as well. But as it became clear that quinine didn't work against the flu and mask wearing did help people eventually came around, as I am optimistic they will today. So, yes, it is a challenge to get good information out there because it takes time to do good studies and then get the answers out there in a way so people know they're legitimate. But what's important for people to understand is that scientists are still going through the process of doing those studies and we need patients help to participate in them so we can understand this disease.

Bottom line: 'Wear a mask!'

When I asked Karanjia for this interview, I had explained my love of pop culture and had mentioned Max Brooks' novel "World War Z." That inspired her to read the book, which we discussed.

"I think there are a number of things that Max Brooks got right in his zombie apocalypse book," she said. "So one of the most salient ones, I think, is because no one wanted to believe that a serious pandemic was occurring in the book. There was a delay in using the right tactics to combat it, which resulted in a lot of preventable death and suffering. So while COVID is not a zombie apocalypse, it would be great if we could learn from 'World War Z,' take this pandemic seriously and initiate appropriate containment tactics to prevent it from snowballing as opposed to the book."

If there is one thing Karanjia hopes people take away from her discussion here it's this:

"You SHOULD be afraid of getting COVID, because Ive seen it kill young healthy people or leave them horribly disabled," she told me. Many of my patients' families chose to let their loved ones die because the brain damage they sustained was so severe. I have now seen multiple young COVID patients with neurologic complications that resulted in their death or left them terribly disabled. I have not seen that with the flu in over 15 years of treating patients. We can get through this faster and with less economic damage and lives lost if we all wear masks and social distance.

It is really that simple.

Beth Accomando Arts & Culture Reporter

I cover arts and culture, from Comic-Con to opera, from pop entertainment to fine art, from zombies to Shakespeare. I am interested in going behind the scenes to explore the creative process; seeing how pop culture reflects social issues; and providing a context for art and entertainment.

To view PDF documents, Download Acrobat Reader.

Read the original here:
COVID And The Brain: 'You Should Be Afraid' - KPBS

Explaining the Association Between COVID-19 and Stroke – Medscape

Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

This transcript has been edited for clarity.

Mark J. Alberts, MD: Hello, and welcome to this Medscape update. My name is Dr Mark Alberts. I'm chief of neurology at Hartford Hospital and I'm a vascular neurologist.

Today I'm joined by my friend and colleague, Dr Jesse Weinberger. I'm going to let Dr Weinberger introduce himself now. Jesse?

Jesse Weinberger, MD: Thanks. I'm Jesse Weinberger. I'm a stroke neurologist at Mount Sinai and I'm coming to you from the neurovascular lab. I'm the director of the neurovascular laboratory at Mount Sinai.

Alberts: What we're going to be talking about for the next little while is something that I'm sure many of our colleagues on the Medscape platform are interested in, which is the association between COVID-19 infections and cerebrovascular disease.

Here at Hartford, we have seen our fair share of COVID-19 folks with strokes. I'm sure that Jesse, being at Mount Sinai, at sort of ground zero in New York, has also seen his fair share. So let's talk about the overall landscape of COVID-19associated strokes.

Jesse, what have you seen, and [can you speak to] the epidemiology and some of the numbers?

Weinberger: Mount Sinai has affiliates all over Manhattan and in Queens. And it was our Queens affiliates, Elmhurst and Mount Sinai Queens, that were in the epicenter of stroke in New York. If you recall from the news, Elmhurst was the hospital that got flooded over and we got a lot of their transfers.

We have one interventional team that services all the hospitals and moves [to the patients] to avoid the patients having to be moved. That makes it much faster to get a fast thrombectomy time.

Our group has probably seen the most stroke COVID-19 patients because we've had the most COVID-19 patients. In terms of epidemiology, one of the papers that our interventional group is putting together compares the number of interventions we do in a given month prior to COVID to how many we're doing now. They found that we're doing twice as many interventions for large vessel thromboses than usual, over 50% of which were on COVID-19 patients.

These were mainly young patients who were forming clots in the arteries, and with no evidence of dissection or a cardiac source. [These were] spontaneous thrombi affecting large cerebral vessels, like the middle cerebral artery.

Alberts: One of the things that we've seen here at Hartfordand I want to see if your experience in New York has been the sameis that in general, we have seen a decline in terms of routine stroke patients and routine interventions, like use of TPA and endovascular therapy.

I think our colleagues around the country have also seen a general decline in stroke patients overall, even though as I've seen and as you just pointed out, in those COVID-19 patients, certainly there seems to be some coagulation and ischemic issues. Have you see an overall decline in the nonCOVID-19 stroke population?

Weinberger: Not so much a decline as that they're coming in a day or two after. They're not coming in for the acute intervention, which is unfortunate because some of them might have been candidates for TPA or thrombectomy, and instead they come in too late.

Alberts: COVID-19 is attacking people in different age groups and [results in] very high mortality with older folks and those in nursing homes. But what about this younger population we're seeing?

Weinberger: These are patients primarily under 50. They're young patients that are getting this, for some reason.

Alberts: As we both know, there have been several reports about COVID-19 causing somewhat of a hypercoagulable state. We've certainly seen many folks with high D-dimers, DVTs, PEs, as well as ischemic stroke. Has that been your experience in New York, Jesse?

Weinberger: Well, we see a lot with elevated D-dimers. We had four patients with acute thrombi in the carotid bifurcation and two of them had normal D-dimers, so we weren't sure exactly why that happened. Some of the patients have had anticardiolipin antibody.

My rheumatology colleagues say that they're seeing many rheumatologic disease mimics from the COVID-19 infection that turn into Kawasaki syndrome. It may be that they're having an immune response that mimics a lupus anticoagulant or anticardiolipin antibody that contributes to the thrombosis.

Alberts: Very interesting. As we talk about specific stroke syndromes, we have seen two varieties. Number one are folks with MRIs showing a bunch of small strokes all over the place, like you could see in somebody hypercoagulable with cancer or with a central embolic source.

We're also seeing the same thing that you describe, which is large vessel strokes like M1 inclusions, in folks who don't have a good reason for it. There's no atrial fibrillation and they're not really atheropathic, per se. They're just having in situ clots. Are you seeing the same variety?

Weinberger: Oh, yeah. In addition to the ones that I mentioned with the large vessel thromboses, we're seeing many with multiple small infarcts, but we don't find anything in the heart causing it. We think it's probably multiple angiopathy due to COVID-19 thromboses.

Alberts: In the vascular studies that we've done here in the folks with strokes all over the place, I don't think we've seen many with an underlying vasculopathy. The vessels, as near we can tell, look normal. They're just having clots all over the place, producing this shotgun image of small strokes in different vascular territories.

Weinberger: Right. We're seeing the same thing, but it does seem to us that it was direct thromboses in these vessels rather than a shower of emboli.

Alberts: And it could be both. It's hard to tell. But I agree: We're not seeing any obvious central embolic source like clots in the left ventricle or left atrium, or myxomas or anything like that.

Weinberger: Our echocardiographers didn't want to do echos on the COVID-19 patients. Fortunately, the first one we sent to them actually had an atrial septal defect. After that, they acquiesced to doing all of our studies, and no one else had any positive [cardiac] findings.

Alberts: We and others are seeing folks with DVTs and PEs, which speaks to a hypercoagulable state, obviously.

Weinberger: Right. The people I'm thinking of that had the multiple infarcts also had PEs. They had both, so it wasn't a paradoxical embolus.

Alberts: Right. Again, when you have D-dimers in the thousands, it's not too surprising that we would see that.

How about your approach to treatment in terms of IV lytic therapy versus endovascular therapy? I know some of this is dictated by the underlying CTA results, but are most of your patients being treated with TPA, endovascular therapy, or both?

Weinberger: We approach it the same way as with any other stroke patient. If they're in the window for TPA, we'll give it and then proceed to the thrombectomy if they need it. We've had a couple of patients that actually got better right after the TPA, which was nice.

Alberts: Yes, very gratifying. How about the response to endovascular therapy? Are you able to do a thrombectomy or otherwise open up these vessels, or do some of them look like the clot is old and it's like a brick?

Weinberger: No, they mainly open with thrombectomy, but the results are a little bit mixed. I don't think we see the same percentage of recoveries with these patients as we do under normal circumstances.

Alberts: Yeah, we're tending to see that most of these clots are removable or otherwise treatable. To me, this speaks to the fact that they are probably acute, not like an old clot that's been sitting in the heart for months, which then embolizes and it's hard as a rock and you have a hard time getting it out.

Weinberger: That's probably why they responded to TPA as well.

Alberts: Right. Fresh clots. Now, you did mention that the overall recovery was not as good as you were hoping for. Can you shed some light on this?

Weinberger: I can't really. It's just an observation from a few patients, but it seems like they don't do as well.

Alberts: If your patients are like my patients, most of them are not on the primary neurology or stroke service. We're seeing them as consults because they're in the MICU or another ICU service due to their underlying COVID-19 infection. Is that your experience also?

Weinberger: No. We're admitting them to the neurology ICU or to the stroke service floor. We're taking care of the COVID-19 patients for primary care as well.

Alberts: Do you think COVID-19 patients with stroke as a complication differ from those coming in with a stroke, but in whom you then find have COVID-19?

Weinberger: Interestingly, when many patients go for CT angiography, they're not diagnosed with COVID-19. We pick it up as having a ground-glass appearance in the lungs and then we get to swab them. Once we see that, we assign them to the COVID-19 floor until proven otherwise.

Alberts: My rule of thumb nowadays is that anybody who comes in with a stroke has COVID-19 until proven otherwise.

Weinberger: Right.

Alberts: On the back end, are you having luck sending these folks to rehab or a nursing home? What is the paradigm like in the New York City area?

Weinberger: Actually, there are several nursing homes that take them for subacute rehabilitation. Our acute rehab service isn't taking them, but they're going to subacute centers.

Alberts: Got it. I think we're fortunate because we've had a number of these patients who actually made a good recovery and the nursing homes and rehab center were willing to take them. So we were able to offload some of the patients from the hospital to make room for the next round.

Weinberger: Actually, in the past couple of weeks that I've been on, it's really been slowing down. We haven't had a COVID-19 stroke patient in a couple of weeks now.

Alberts: Wow!

Weinberger: Mitigation.

Alberts: Mitigation is good.

Weinberger: The overall number of COVID-19 patients admitted to the Sinai system is going down and so are the strokes. The other thing is that as soon as somebody is diagnosed with COVID-19, they're being anticoagulated with Lovenox (enoxaparin) because of the known thrombosis risk.

Alberts: That's a great point. We also have a hospital policy that anybody admitted with COVID-19 gets at least prophylactic doses of an anticoagulant. Obviously, if they have ongoing thromboses, then they will get therapeutic doses.

Alberts: What about the lack of taste and smell? Are you seeing that in many of your patients?

Weinberger: I haven't noticed that. Frankly, I probably didn't ask about it.

Alberts: Yeah. Obviously, if they're really sick with a stroke or if they're intubated [it would be difficult]. But it's been reported by CDC that it's one of the cardinal signs to ask about. It would imply cranial nerve involvement, right?

Weinberger: Right. Going up the olfactory nerve into the brain.

Alberts: I think here in Connecticut, we're a few weeks behind you in terms of the curveor maybe in front of you, depending on how you look at itbut like you, we have a number of different hospitals throughout the state [with varying rates]. St. Vincent's, which is in the western part of Connecticut in Fairfield County, is still seeing high volumes. But in general they are all coming down, which is very encouraging.

Weinberger: The question is whether it will stay coming down when we start trying to open up the city again.

Alberts: Right. The other interesting thingand I don't have any answers or insightsis to see if there might be some sort of postCOVID-19 syndrome, like pulmonary fibrosis or some other systemic manifestations, after the infection.

You mentioned the autoimmune component. Like many autoimmune diseases, they do have the potential to fluctuate, and it's just going to be very interesting to have these patients followed long-term for 3 months, 6 months, a year, just to see if there are any long-term sequelae, either autoimmune or postinfectious or something in that realm.

I don't have any answers or insights, but that's why they call it "novel." This is a new disease that we don't have much experience with.

Weinberger: Correct.

Alberts: I think we've touched on a lot of the points about epidemiology, acute treatment, and long-term outcomes.

Thank you to our Medscape audience for joining us. I wish that all of our colleagues be well and that their patients have a rapid recovery.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Originally posted here:
Explaining the Association Between COVID-19 and Stroke - Medscape

COVID-19: Recommendations for Treating MS and Related… : Neurology Today – LWW Journals

Article In Brief

Most therapies for multiple sclerosis and neuromyelitis optica spectrum disorder should be continued and not stopped during the COVID-19 pandemic, MS experts agree. But there are also pros and cons of starting certain B-cell depleting and other therapies.

For most patients with multiple sclerosis (MS), the benefits of staying on therapy will outweigh the risks of stopping due to concerns over COVID-19, according to new guidelines for treating MS during the pandemic.

Even in those with a documented mild case of COVID-19, continued treatment with most MS medications may be reasonable, the guidelines recommend. However, they emphasize: Neurologists should have a lower threshold for stopping treatment in people taking therapies with greater immunosuppressive effects and those with risk factors for a more severe disease (older age, comorbidities), or if COVID-19 symptoms are deteriorating.

Published online in Neurology on April 2 by a team of MS neurologists from the United States, Australia, The Netherlands, and the United Kingdom, the new guidelines cover both MS and neuromyelitis optica (NMO) spectrum disorder. The guidelines differ only slightly from guidelines previously released by the National Multiple Sclerosis Society, the Italian Society of Neurology, and other groups.

Even so, MS neurologists not involved in preparing the recommendations welcomed their publication.

Kudos to the authors for taking the time to do this when we're all under so much pressure, said Annette Langer-Gould, MD, PhD, the regional lead for clinical and translational neuroscience for the Southern California Permanente Medical Group/Kaiser Permanente.

Based on prior experience with other viral infections in people with MS, the recommendations will likely need to be updated as data emerges from actual cases of patients who develop COVID-19.

New data are emerging quickly from clinical experience and from registries that have been established for MS patients with COVID-19, said the first author of the paper, Wallace Brownlee, MD, PhD, a neurologist with the Queen Square MS Centre and the National Hospital for Neurology and Neurosurgery in London.

Indeed, one recommendation in the paper is already out of date. Face masks are only recommended for people who are coughing or sneezing, or for those caring for a patient with suspected COVID-19 infection, the guidelines stated. By now, of course, most public health recommendations call for wearing face masks whenever people are in public and are unable to stay at least six feet away from others.

Otherwise, MS neurologists told Neurology Today that they had few if any disagreements with the guidelines as published. In particular, they all agreed that IV treatments with drugs known to cause significant declines in immune function should be avoided or delayed as long as possible.

Dr. Brownlee and other MS neurologists urged any neurologist treating a patient with MS who develops a COVID-19 infection to submit data to one of the patient registries that have been established. In North America, the National MS Society and the Consortium of MS Centers have established the Coronavirus and MS Reporting Database at http://www.covims.org.

For MS patients who are just beginning treatment, Dr. Brownlee said, We recommend that neurologists take a cautious approach to initiating patients on treatments that can be associated with periods of significant immune suppression, including autologous hematopoietic stem cell transplantation, alemtuzumab and cladribine.

Although acute MS relapses are often treated with a short course of high-dose IV methylprednisolone, such treatments should be avoided during the pandemic, the guidelines stated. High-dose steroids hasten the recovery from MS relapses, but do not influence the final degree of recovery, the paper noted. Because steroids can increase the risk of infection, neurologists should have a higher threshold for offering them during the COVID-19 pandemic, according to the guidelines.

A few disease-modifying therapies (DMTs), including interferon-beta and glatiramer acetate, do not increase the risk of systemic infections. Other DMTs, however, do have immunosuppressive effects with alterations in lymphocyte number, trafficking, proliferation and function, with an increased risk of infections, including viral infections and respiratory infections, the guidelines stated.

People with MS who are profoundly lymphopenic, for example, after treatment with alemtuzumab or less commonly during treatment with cladribine, fingolimod or dimethyl fumarate, may be at higher risk.

As reasonable as such concerns appear to be at this time, the paper noted that no data specific to MS patients with COVID-19 has yet emerged supporting them.

For patients scheduled for routine treatment with alemtuzumab or cladribine, We recommend delaying treatment with these therapies, the paper stated. Likewise, standard every six-month dosing with ocrelizumab or rituximab can also be delayed in most cases.

B-cell depletion frequently lasts much longer than the scheduled dosing interval, the recommendations noted. Extended interval dosing should be considered, especially in patients who are B-cell depleted...or [in] those with low levels of immunoglobulin-G. Extended interval dosing is already widely used in patients treated with natalizumab because of observational data showing a reduced risk of progressive multifocal leukoencephalopathy. Whether this approach reduces the risk of other infections is unknown but should be considered during the COVID-19 pandemic to reduce hospital visits.

For MS patients who are hospitalized with a severe COVID-19 infection, consideration should be given to stopping treatment, the guidelines state. Treatment can be restarted after four weeks, or when symptoms have fully resolved, keeping in mind the risk of rebound MS activity with S1P modulators and natalizumab. Neurologists should alert intensive care physicians to the importance of fever management in people with MS.

Patients with neuromyelitis optica spectrum disorder who do not have a COVID-19 infection should be encouraged to continue attack-prevention therapies, because relapses of NMOSD can be devastating. If the need to stop or delay treatment in such patients arises, then moderate dose corticosteroids (e.g. prednisolone 20mg) can be used to prevent relapses in the short to medium term, the guidelines recommended.

Dr. Langer-Gould echoed the guidelines' concern about MS drugs associated with lymphopenia.

With COVID-19, we're seeing something very unusualthat in the people who do poorly, almost all of them have lymphopenia when they're admitted, she said. Any drug you're on that is causing T-cell lymphopenia is more likely to increase your risk of getting a severe case of COVID. So they have correctly identified the ones to stay away from, including alemtuzumab and cladribine, but I would add fingolimod, dimethyl fumarate and other S1P modulators to that list.

Starting in early March, she said, We actively reached out to patients on dimethyl fumarate and S1P inhibitors and are switching them, depending on their disease severity, either to interferon and glatiramer acetate, or if they had active disease, then we switched them to either rituximab or natalizumab.

But for all her patients other than those on interferon-beta or glatiramer acetate, she said, We're telling them to consider themselves immune-suppressed. They should immediately get themselves tested for COVID-19 if they develop fever or shortness of breath.

Her practice recently had an MS patient who had been stable on natalizumab until suddenly developing a high titer positive antibodies against JC Virus. The patient is now at increased risk of progressive multifocal leukoencephalopathy, Dr. Langer-Gould said.

Our plan had been to switch them to rituximab, but then they developed a COVID-19 infection and are mildly symptomatic. That's a big problem, because you need to pre-treat for rituximab with steroids, potentially increasing the risk of a more severe case of COVID-19, and the infusion is long, which raises the risk of infecting the nursing staff at the infusion center. We've decided to give her another dose of natalizumab eight weeks after her last dose. It's a short infusion, and we don't have to pre-treat with steroids. But what's the right decision?

Timothy L. Vollmer, MD, FAAN, professor of neurology at the University of Colorado Health Sciences Center and medical director of the Rocky Mountain MS Center, said that most of his group's patients are on ocrelizumab.

We probably didn't need to be dosing patients every six months, he said. As a result of COVID-19, we're reevaluating the dosing strategy. We're checking their B cells and antibody levels, and if they are still depleted, we wait another two months. It will take some patients a year or more before they begin to normalize their B cells. Dosing less frequently will also decrease costs substantially and make the drug more attractive for patients to use.

One clear effect of the COVID-19 pandemic is that many MS patients are reaching out to their neurologists about what it means for them.

My colleagues and I have been receiving many phone calls and messages about our recommendations, said Bardia Nourbakhsh, MD, assistant professor of neurology at Johns Hopkins. We try to extrapolate the information that we have from other viral infections.

Dr. Nourbakhsh said he had been contacted the week of April 13 by a community neurologist whose patient had developed a severe, disabling, demyelinating relapse that did not improve after IV steroids.

My recommendation was for the neurologist to set up a plasma exchange, he said. I would not delay the treatment of a serious relapse that could affect the mobility or vision of the patient. Treating an actual condition takes precedence over the possibility of coming into contact with coronavirus.

Bianca Weinstock-Guttman, MD, director of the Jacobs MC Center at the University of Buffalo and director of its Pediatric MS Center of Excellence, said she recommends that all MS patients should be reminded, now more than ever, to follow basic daily health recommendations.

Supportive recommendations for patients include keeping interactions with friends and relatives through video, exercising via YouTube, maintaining a healthy diet, and vitamin supplementation, especially vitamin D, she said.

Joseph Berger, MD, FAAN, professor and associate chief of the Multiple Sclerosis Division at the University of Pennsylvania School of Medicine, noted that the very same tendency of some MS drugs to suppress immune function could in fact benefit COVID-19 patients who develop acute respiratory distress syndrome (ARDS).

Individuals who end up developing ARDS are not dying because of unsuppressed viral replication, Dr. Berger said. Rather, it's an overly robust immune response, a cytokine storm, that appears to give rise to the ARDS. Many of the drugs we use may actually have a beneficial effect on the phase of the illness that results in high morbidity and mortality.

He pointed out that a non-randomized, open-label trial is underway in China to test the effect of giving fingolimod to 30 patients with COVID-19 in order to prevent ARDS.

Dr. Weinstock-Guttman said another drug that might block the cytokine storm is tocilizumab, approved to treat moderate to severe rheumatoid arthritis.

IL-6 blockade was shown beneficial recently also for NMO patients, so it will be interesting to see COVID-19 patients' outcome when treated with antiIL-6 products for a previous underlying disease, Dr. Weinstock-Guttman said.

Dr. Langer-Gould expressed caution about the approach. There's a big difference between using a drug like fingolimod for a few days to reduce a cytokine storm versus having someone on it as a long-term therapy, which results in chronic T-cell suppression and, in rare instances, fatal viral infections, she said.

If your T-cells are markedly diminished and you are infected with COVID-19, your body would have a hard time clearing that virus and you would potentially be at higher risk of developing pneumonia, ARDS, and, potentially, multisystem organ failure.

She added that none of the immunologists she works with are recommending a T-cell-depleting therapy for COVID-19. Most of the patients we're seeing already have low lymphocytes, she said. The virus is taking down the CD4 and CD8 cells. I don't think anyone would feel comfortable giving a drug that further suppresses CD4 and CD8.

Dr. Brownlee agreed that while the potential benefit of fingolimod as an acute treatment to prevent ARDS is interesting, we need to be careful about being too quick to translate hypotheses into treatment. It's not enough to inform patient care at the moment.

Ultimately, such questions can only be answered as more experience is gained in treating MS patients who develop a COVID-19 infection, Dr. Berger said. Time will tell, he said. It's going to be important to get real-world data from the registries to see whether or not what we think is correct. Is there a signal for any of these MS drugs? We'll know when the registries reveal their data. It's going to take the participation of neurologists around the world to distill out the treatments with one or another drug.

Dr. Brownlee has accepted speaker honoraria and/or participated in advisory boards for Biogen, Merck, Mylan, Novartis, Roche and Sanofi-Genzyme. Dr. Vollmer has received compensation for lectures and consultancy with Biogen IDEC, Genentech/Roche, Siranax, Celgene, EMD Serono, and Novartis. He has received research support from Rocky Mountain MS Center, Biogen,Actelion, Roche/Genentech;, F. Hoffman-La Roche, Ltd., and TG Therapeutics, Inc. Dr. Berger has received honoraria and an institutional grant from Biogen, and Genentech/Roche. He has received honoraria as a consultant for Celegene, Millennium/Takeda, Novartis, Inhibikase, Excision Biom Amgen, Shire, Dr. Reddy, Serono, Morphic, Encycle, Merck, and MAPI. Dr. Nourbarkhsh served on the advisory board for Jazz Pharmaceutical. Dr. Langer-Gould had no disclosures.

Excerpt from:
COVID-19: Recommendations for Treating MS and Related... : Neurology Today - LWW Journals

Poverty, location and insurance status play major role in epilepsy care – UAB News

UAB researchers say lack of financial resources and health insurance, as well as living in the South, are keys to disparities in epilepsy care.

UAB researchers say lack of financial resources and health insurance, as well as living in the South, are keys to disparities in epilepsy care.Treatment of epilepsy in America varies depending on several social factors, including income, insurance and region, according to new research from the University of Alabama at Birmingham published online on April 12 in Epilepsy and Behavior.

Using data from the 2013, 2015 and 2017 National Health Interview Survey administered by the Centers for Disease Control and Prevention, the researchers found that poverty is associated with a lower likelihood of anti-seizure medication use and the uninsured are less likely to visit a neurology provider, while people in the Northeast are more likely to see a neurologist. They also found that epilepsy treatment did not vary by race/ethnicity or immigrant status.

According to the United States Institute of Medicine, there are significant social barriers to optimal care and health outcomes for people/persons with epilepsy (PWE), said Magdalena Szaflarski, Ph.D., associate professor in the UAB Department of Sociology in the College of Arts and Sciences and the studys first author. This study examined those barriers, as this knowledge is essential and identifies potential points of intervention at the policy, public health and health care system levels. Social factors, not only clinical, need to be addressed in order to improve care and outcomes in this patient population.

Szaflarski says insurance was a key social predictor of seeing a specialist, while poverty was a key barrier in medication use.

Magdalena Szaflarski, Ph.D, says that poverty is associated with a lower likelihood of anti-seizure medication use.The association between anti-seizure treatment and poverty extended over and beyond insurance status, indicating that not only access to care but also poverty effects more broadly (e.g., distance and transportation barriers) restrict opportunities for quality care and treatment among PWE, she said.

The study documented several disparities in visits to an epilepsy provider and anti-seizure medication use in the U.S. sample of adult PWE and indicated that a large proportion of PWE continue to experience recurring seizures, an alarming trend, according to the authors, due to the broad array of advanced treatment options currently available.

In our study, uninsured and people residing outside of the Northeast were less likely to visit an epilepsy provider in the past year compared with their insured and Northeast-based counterparts, said Jerzy Szaflarski, M.D., Ph.D., director of the UAB Epilepsy Center in the School of Medicine and a study co-author. Notably, the U.S. South has high burden of disease including epilepsy and has recently been referred to as the Epilepsy Belt. In this study, the South had the highest proportion of epilepsy cases, but much lower rates of neurology visits than in the Northeast.

In particular, Szaflarski says, the findings are consistent with previous analysis of supply and demand for neurologists nationally and state-by-state.

At the national level, over 1,800 more neurologists are needed to meet the demand, and this is reflected in previously published state-by-state estimates: The demand for neurologists in the majority of the states was estimated at 20 percent or higher than supply, he said. Only a few states, all but one in the Northeast region and the District of Columbia, had a supply of neurologists greater than the demand.

Magdalena Szaflarski says the study contributes to better describing socially based variations in two aspects of epilepsy treatment: use of epilepsy specialized services and anti-seizure medication use.

Jerzy Szaflarski, M.D., Ph.D., says there is a shortage of 1,800 neurologists in the United StatesInformation from this study can guide health and disability policies, public health programs and health care delivery systems to strengthen resources and access to care/treatment for PWE, especially for people with treatment-resistant seizures, she said. Engaging patients/families in policy and program development, as well as research, is also essential for further understanding of the needs of this population and opportunities for improvements.

Co-authors on the study are Joseph D. Wolfe, Ph.D., associate professor of sociology, Joshua Gabriel S. Tobias, graduate assistant in sociology, and Ismail Mohamed, M.D., associate professor of pediatric neurology.

This study was supported by the Interdisciplinary Innovation Team Award from theUAB College of Arts and Sciences, with a contribution by theUAB Center for Clinical and Translational Science(CCTS;National Institutes of Health grantUL1TR003096).

See the original post:
Poverty, location and insurance status play major role in epilepsy care - UAB News

How could Covid-19 and the body’s immune response affect the brain? – MIT News

To get ahead of the possible long-term neurological problems from infection, multiple labs in The Picower Institute for Learning and Memory at MIT have begun pursuing research to determine whether and how it affects the brain, either directly or via the bodys heightened immune response. If it indeed does, that would be consistent with a history of reports that infections and immune system activity elsewhere in the body may have long-term impacts on mental health.

While some scientists, for instance, suspect a role for infectious diseases in neurodegenerative disorders such as Parkinsons disease or dementias, Picower Institute Member Gloria Choi and Harvard University immunologist Jun Huh have meticulously traced the pathway by which infection in a pregnant mother can lead to autism-like symptoms in her child and how, counterintuitively, infection in people with some autism spectrum disorders can temporarily mitigate behavioral symptoms. With deep expertise in neuro-immune interactions, as well as in the neural systems underlying the sense of smell, which is reported to be lost in some Covid-19 patients, Choi is planning several collaborative coronavirus studies.

With these various suspected neurological symptoms, if we can determine the underlying mechanisms by which the immune system affects the nervous system upon the infection with SARS-CoV-2 or related viruses, then the next time the pandemic comes we can be prepared to intervene, says Choi, Samuel A. Goldblith Career Development Assistant Professor of Applied Biology in the Department of Brain and Cognitive Sciences.

Like Choi, Picower Professor Li-Huei Tsai is also planning studies of the neurological impact of Covid-19. Tsais studies of Alzheimers disease include investigation of the blood-brain barrier, which tightly gates what goes into and out of the brain through the circulatory system. Technologies that her lab is developing with collaborators including MIT Institute Professor Robert Langer put the team in a unique position to assess whether and how coronavirus infection might overrun or evade that safeguard.

It is critical to know how the coronavirus might affect the brain, Tsai says. We are eager to bring our technology to bear on that question.

Neuro-immune interactions

Choi is considering three lines of coronavirus research. Together with Picower Institute colleagues Newton Professor Mriganka Sur and Assistant Professor Kwanghun Chung, she hopes to tackle the question of anosmia, the loss of smell. Choi has studied the olfactory system in mice since her graduate and postdoc days. Moreover, a key finding of her neuroimmunology research is that because neurons express receptors for some of the signaling molecules, called cytokines, emitted by immune system cells, those interactions can directly affect neural development and activity. Working in mouse models, the team plans to ask whether such an impact, amid the immune systems heightened response to Covid-19, is occurring in the olfactory system.

Based on her and Huhs studies of how maternal infection leads to autism-like symptoms in their offspring, they are concerned about two other aspects of coronavirus infection. One builds on the finding that the risk of offspring developing neurological problems depended strongly on the composition of the pregnant mothers gut microbiome, the populations of bacteria that everyone harbors within their body. Given the wide range of outcomes seen among coronavirus patients, Choi and Huh wonder whether microbiome composition may play a role in addition to factors such as age or underlying health conditions. If that turns out to be the case, then tweaking the microbiome, perhaps with diet or probiotics, could improve outcomes. Working with colleagues in Korea and Japan, they are embarking on studies that will correlate microbiome composition in patients with their coronavirus outcomes.

Over the longer term, Choi and Huh also hope to study whether Covid-19 infection among pregnant mothers presents an elevated risk of their offspring developing neurodevelopmental disorders like autism. In their research in mice, they have showed that given a particular maternal microbiome composition, immune cells in pregnant mice expressed elevated levels of the cytokine IL-17a. The molecule directly influenced fetal brain development, causing neural circuits governing autism-like behavioral symptoms to develop improperly. The pair aim to assess whether that could happen with coronavirus.

Covid-19 access to the brain

A major question is whether and how the SARS-CoV-2 virus can reach the central nervous system. Tsais lab may be able to find out using an advanced laboratory model of the blood-brain barrier (BBB), whose development has been led by postdoc Joel Blanchard. In a study in press, he has shown that the model made of human astrocytes, brain endothelial cells, and pericytes cultured from induced pluripotent stem cells closely mirrors properties of the natural BBB, such as permeability. In collaboration with Langer, the team is integrating the model with induced pluripotent stem cell-derived cultures of neurons and other crucial brain support cells, like microglia and oligodendrocytes, on a chip (called a miBrain chip) to provide a sophisticated and integrated testbed of brain cell and cerebral vascular interaction.

With the miBrain chip platform Tsais lab plans several experiments to better understand how the virus may put the brain at risk. In one, they can culture miBrain chips from a variety of individuals to see whether the virus is able to permeate the BBB equally or differently in those personalized models. They can also test another means of viral entry into the brain whether the bodys immune system response (a so-called cytokine storm) increases the BBBs permeability by using blood serum from Covid-19 patients in the miBrainChip model.

Yet another way the virus might spread in the nervous system is from neuron to neuron via their connections called synapses. With cultures of thousands of neurons, the miBrain chip platform could help them determine whether thats the case, and whether specific kinds of neurons are more susceptible to becoming such conduits.

Finally, there may be genetic differences that increase susceptibility to viral entry to the brain. Using technologies like CRISPR/Cas9, the team can engineer such candidate risk genes into the BBBs to test whether permeability varies. In their Alzheimers disease research, for example, they study whether variations in a gene called ApoE causes different degrees of amyloid proteins plaque buildup in the BBB model.

The potential interactions among the virus, the microbiome, the immune system, and the central nervous system are likely to be highly complex, but with the expertise, the tools, and strong collaborations, Picower Institute researchers see ways to help illuminate the possible neurological effects of coronavirus infection.

Go here to read the rest:
How could Covid-19 and the body's immune response affect the brain? - MIT News

New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and – PharmiWeb.com

ROCKLAND, Mass., May 23, 2020 /PRNewswire/ --EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced data on the long-term efficacy and safety profile of evobrutinib, an investigational, oral, highly selective Bruton's Tyrosine Kinase (BTK) inhibitor in adult patients with relapsing multiple sclerosis (RMS). The results from the Phase II open-label extension (OLE) study will be presented as a late-breaker at the European Academy of Neurology (EAN) 2020 Virtual Congress.

"These data demonstrate evobrutinib has a sustained and high impact on annualized relapse rate over 108 weeks," said Luciano Rossetti, Head of Global Research & Development for EMD Serono. "Greatest efficacy was clearly associated with BTK occupancy, and this further validates our choice of dose for the Phase III program. We are also encouraged by evobrutinib's breadth of consistent safety data, including no increase of serious infections in more than 1,200 patients up to two years."

Annual relapse rate (ARR) results in the double-blind phase of the study were maintained over the open-label extension, with patients receiving evobrutinib 75mg BID (twice a day) in the double-blind phase showing an ARR of 0.11 (95% CI 0.040.25) at week 48, and of 0.12 (0.060.22) for the 108-week period.

The data from the Phase II study continues to demonstrate that BID dosing can achieve higher efficacy than QD dosing on clinical outcomes, as demonstrated by reduced ARR. Modelling data show that greater than 95% BTK occupancy at trough is necessary in nearly all patients to achieve highest efficacy and this can be best achieved with BID dosing.

Data previously published in the New England Journal of Medicine reported the findings of the Phase II study where at 24 weeks, evobrutinib significantly reduced the cumulative number of T1 Gd-enhancing lesions compared to placebo, meeting its primary endpoint. At week 48, all patients could enter the OLE which assessed the long-term efficacy and safety of evobrutinib.

"The 108-week efficacy and safety data for evobrutinib through the double-blind and the OLE period are very robust," noted Dr. Xavier Montalban, Chairman & Director Neurology-Neuroimmunology Department & Neurorehabilitation Unit, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain. "This, combined with the high selectivity of evobrutinib, suggests that evobrutinib may offer a promising approach to MS treatment."

Of 267 randomized patients, 213 completed 108 weeks of treatment (48 weeks in main study and 60 weeks in OLE). Evobrutinib was generally well-tolerated, with the safety profile maintained during the OLE including no increase in infections and overall no new safety signals identified. Consistent with evobrutinib's high selectivity, patients participating in the trial experienced no systemic side effects, such as gastrointestinal disturbances. In the Phase II trial, the most commonly observed adverse events of any grade associated with evobrutinib included nasopharyngitis and increases in levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lipase.

The transient elevated liver aminotransferases were restricted to the first 24 weeks following evobrutinib treatment initiation and were not observed in the OLE in patients continuing treatment with evobrutinib.

Evobrutinib is entering Phase III trials following the results of the Phase II clinical trial, which met its primary endpoint over 24 weeks of treatment. The two new trials, EVOLUTION RMS 1 and 2 are multi-center, randomised, parallel group, double-blind, double dummy, active-controlled studies of evobrutinib with teriflunomide, in participants with RMS. Each trial's primary endpoint is patients' ARR after 96 weeks of treatment. Secondary endpoints include the appearance of new or enlarging T2 lesions assessed by MRI scans and progressing disability as measured by the Expanded Disability Status Scale (EDSS).

About EvobrutinibEvobrutinib (M2951) is in clinical development to investigate its potential as a treatment for multiple sclerosis (MS). It is an oral, highly selective inhibitor of Bruton's Tyrosine Kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages.Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. BTK inhibition is thought to suppress autoantibody-producing cells, which preclinical research suggests may be therapeutically useful in certain autoimmune diseases. The global Phase III clinical development programme evaluating evobrutinib in MS includes two pivotal studies, EVOLUTION RMS 1 and 2. Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world.

About Multiple SclerosisMultiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

EMD Serono, Inc. and Multiple SclerosisFor more than 20 years, EMD Serono has been relentlessly focused on understanding the journey people living with MS face in order to create a meaningful, positive experience for them and the broader MS community. However, there is still much that is unknown about this complex and unpredictable disease. EMD Serono is digging deeper to advance the science.

About EMD Serono, Inc. EMD Serono - the biopharmaceutical business of Merck KGaA, Darmstadt,Germany, in the U.S. andCanada- is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases. The business is committed to transforming lives by developing and delivering meaningful solutions that help address the therapeutic and support needs of individual patients. Building on a proven legacy and deep expertise in neurology, fertility and endocrinology, EMD Serono is developing potential new oncology and immuno-oncology medicines while continuing to explore potential therapeutic options for diseases such as psoriasis, lupus and MS. Today, the business has approximately 1,500 employees around the country with commercial, clinical and research operations based in the company's home state ofMassachusetts.www.emdserono.com.

Your Contact Alice McGrail 1-781-738-8791

View original content:http://www.prnewswire.com/news-releases/new-late-breaking-data-at-ean-indicate-evobrutinib-is-the-first-btk-inhibitor-to-report-efficacy-and-safety-in-ms-over-108-weeks-301064619.html

SOURCE EMD Serono

Follow this link:
New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and - PharmiWeb.com

University of Alberta neurologists watch for signs that COVID-19 can attack the brain – Folio – University of Alberta

Neurologists at the University of Alberta are monitoring Edmonton patients diagnosed with COVID-19 for signs that the virus, which can cause deadly respiratory illness, may also attack the brain.

Several manuscripts have been published that suggest patients with severe COVID-19 symptoms also display neurological problems such as confusion, stroke-like attacks, even a hemorrhage in the brain or less severe symptoms such as a loss of the sense of smell, said Christopher Power, professor of neurology and principal investigator of the Brain Power Lab.

Many of the patients who have been found to have neurologic symptoms in the academic reports from Italy, China and the U.S. appear to be the sicker patients, said Jennifer McCombe, associate clinical professor of neurology, who is leading the initiative to look at patients locally.

Power and McCombe, who are both members of theNeuroscience and Mental Health Institute, normally treat patients with multiple sclerosis, HIV and brain infections. Neither is surprised that the novel coronavirus is attacking the brainit is known that other coronaviruses have done sobut they said it is not common and the mechanism is not well understood.

One major question that remains uncertain is to what extent does the virus gets into the brain to cause damage, or are the neurologic symptoms merely a consequence of the systemic effects of overactivation of the immune system? said Power.

Some virusesand were suspicious it is the case with COVID-19infect the lining of the blood vessels and then use that as an entrance into the brain, he said.

Other viruses like HIV actually use a Trojan horse strategy. They infect blood cells and then those blood cells transport the virus into the brain.

Power reported that approximately one per cent of patients with severe acute respiratory syndrome (SARS), caused by another coronavirus that broke out in 2003, also faced neurologic disabilities. They experienced stroke-like events, muscle weakness and peripheral nerve damage. The virus was later detected in brain tissue of some deceased SARS patients.

McCombe plans to examine electroencephalogram and MRI images of COVID-19 patients to understand their neurologic symptoms. A cerebral spinal fluid test has not yet been developed for COVID-19 but would also be very helpful as a window into the brain. Post-mortem analyses can be done to look for signs of the virus in the brain tissue and blood vessels.

McCombe said it is key to understand whether neurologic impairments are caused directly by the virus or whether they are secondary symptoms due to systemic inflammation.

That will really help us decide on potential therapies that could prevent some of these neurologic problems, she said. Do we need to focus on prevention therapies that relate to the issues that are happening elsewhere in the body, or is there viral invasion into the brain and therefore we need to continue to try to find therapies to treat the virus itself?

Power said that anosmia, a loss of the senses of smell and taste, has presented in some otherwise asymptomatic COVID-19 patients. He said anyone who develops this symptom should monitor themselves for other symptoms such as a fever or cough.

McCombe said more dramatic changes in a persons cognitive functioning are a definite cause for concern, because there can be so many potential causes besides COVID-19.

For an isolated change in smell, I would direct people to continue to maintain self-isolation measures, she said. Someone exhibiting confusion or stroke-like symptoms should seek medical attention immediately.

Power said he is speaking daily with other members of the International Society for NeuroVirology so they can work together to track neurologic symptoms in COVID-19 patients.

What we learn from COVID-19, we can apply to the next viral pandemic. The idea is to develop diagnostics and new treatments as soon as possible.

Follow this link:
University of Alberta neurologists watch for signs that COVID-19 can attack the brain - Folio - University of Alberta

Not just the lungs: Some COVID-19 patients show signs of neurological ailments – Waterbury Republican American

Strokes, seizures, loss of smell and taste and other neurological deficits are showing up in patients critically ill with the coronavirus.

Although the virus is classified as a respiratory disorder and primarily damages the lungs, clinicians are seeing patients with a wide array of symptoms, from seizures to hallucinations, brain inflammation, disorientation, delirium and loss of smell and taste.

I had a patient, a young guy, 48, who attended a party in New Rochelle two weeks before and came in with hallucinations and confusion, said Dr. Pooia Fattahi, regional chair of neurology for Trinity Health Of New England. The patient had no fever and only a slight cough. Still, aware some COVID-19 patients show up at hospitals with seizures, strokes and confusion, Fattahi suspected, correctly, that the patient had COVID-19. Three of those who attended the same New Rochelle party ultimately died of the virus.

A third of COVID-19 patients hospitalized in Wuhan, China, suffered neurological symptoms, according to a Chinese study published April 10. Moreover, many of the patients developed these symptoms early; in some cases, the brain abnormalities were their only symptom. Because of that, study authors encouraged front-line clinicians treating patients with brain deficits to consider COVID-19 to avoid delayed diagnosis or misdiagnosis and prevention of transmission.

Precisely why and how the virus attacks the brain penetrating the protective blood-brain barrier is complex and not well understood, said Dr. Jennifer Moliterno, chief of neurosurgical oncology at Yale Department of Neurosurgery and Yale School of Medicine. Other viruses can similarly affect the brain, so its not completely surprising but it is somewhat surprising, she said.

Moliterno speculates that the brain dysfunction seen in COVID-19 patients could originate in two different responses. First, the hyperactive immune system response that physicians have observed in COVID-19-positive patients known as a cytokine storm could trigger an inflammatory response that could cause widespread clotting throughout the body_ That would explain why hospitals are seeing so many patients who manifest with stroke and later test positive for COVID-19.

Second, experts believe COVID-19 infects cells through ACE2 receptors, which are also present in the specialized endothelial cells that make up a critical part of the neurological netting that comprises the blood-brain barrier.

That can allow the virus to leak into the brain, Moliterno explained.

It is also possible that COVID-19 enters the body through the olfactory system, close to the frontal lobes in the brain, which controls cognitive skills, Fattahi and Moliterno said. Inflammation of those lobes is known as encephalitis, whose symptoms include memory loss, behavioral changes, confusion and irritation.

Fattahi noted that anywhere from 5 to 24 percent of COVID-19 patients experienced a difficulty with smell. We dont know but we suspect there are ACE2 receptors that attach the olfactory nerves, which pass through those nerves into the brain, he said.

Those who present with brain disorders, Moltinero said, have a particularly dangerous infection. These patients are really sick, she said. A lot of the patients with the neurological symptoms have the more severe COVID-19 cases.

In Italy, the neurological damage has been so severe among affected patients that a neurologist at the university of Brescia has opened an 18-bed neuro-COVID-19 unit to treat these patients exclusively. Dr. Alessandro Pezzini, associate professor of neurology at the University of Brescia, has advised U.S. doctors to consider the possibility that these brain events are another effect of the virus.

So is a pronounced loss of smell. In South Korea, China, and Italy, about a third of patients who have tested positive for COVID-19 have reported a loss of smell known as anosmia often as their only symptom. That has led some experts to speculate that those who experience a loss of smell might be unsuspecting carriers of the virus who have unwittingly transmitted it to others.

British researchers recently advised doctors to consider loss of smell among the first symptoms of the virus.

There is potential that if any adult with anosmia but no other symptoms was asked to self-isolate for seven days we might be able to reduce the number of otherwise asymptomatic individuals who continue to act as vectors, not realizing the need to self-isolate, Professor Claire Hopkins, president of British Rhinological Society, said in a joint statement released late last month with the British Association of Otorhinolaryngology. Hopkins noted that because these patients do not have the dry cough, fever or shortness of breath that are hallmarks of the virus, they may not meet criteria for testing or self-isolation, though they could be spreading Covid-19.

Dr. R. Peter Manes, a rhinologist at Yale New Haven Hospital, said it was possible that people who lost their sense of smell in the absence of anything else, it can be one of the first signs of COVID-19.

At Saint Marys, Fattahi said he was perplexed to see a seizure in a relatively young patient. I thought, This is a guy who is not a drinker, has no personal history of seizure, so why is he having seizures?' Fattahi said of his 48-year-old patient. I was worried he was maybe exposed to COVID-19 at a party. Unwilling to wait for lab results, Fattahi said he ordered a CT scan, which confirmed his COVID-19 diagnosis. The patient was treated with a battery of antibiotics, anti-seizure medications and hydroxychloroquine and released.

_______________________________________________

WATERBURY Brain malfunction is also a feature of many young, obese patients who are rapidly emerging as at high-risk to contract COVID-19, said Dr. Juan Diego Holguin of Alliance Medical Group.

Once they become infected with the virus, it seems to make their neurological effects more pronounced, Holguin said.

He points to the propensity for the obese to have abnormal pressure of the cerebral spinal fluid. He noted those with a body mass index more than 50 who contract the coronavirus also tend to deteriorate more rapidly.

The progression is unusually fast, Holguin said. We dont know why it progresses so quickly.

Because of the rapid deterioration, he recommends that those younger than 60 with a BMI over 40 should be tested as soon as they develop symptoms: You run the risk of progressing too quickly.

A 6-foot male with a BMI of 50 would weigh 370 pounds. A 54 woman with a BMI of 50 would weigh 290 pounds, Holguin said.

They already have restriction of their thorax from the excess weight. They already have problems getting air to their lungs, he said.

A series of new studies have found obesity may be among the most important predictors in severe COVID-19, particularly among young people. A study from NYU Langone study of patients under age 60 found that those with obesity were twice as likely to be hospitalized. was the second-highest reason why patients were hospitalized with COVID-19.

Tracey OShaughnessy

Related

Continue reading here:
Not just the lungs: Some COVID-19 patients show signs of neurological ailments - Waterbury Republican American